



The Costs of Smoking and Secondhand Smoke Exposure in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005199
Article Type:	Research
Date Submitted by the Author:	06-Mar-2014
Complete List of Authors:	Sung, Hai-Yen; University of California San Francisco, Institute for Health & Aging Chang, Li-Chuan; National Yang-Ming University, Institute of Health and Welfare Policy Wen, Yu-Wen; Chang Gung University, Clinical Informatics and Medical Statistics Research Center Tsai, Yi-Wen; National Yang-Ming University, Institute of Health and Welfare Policy
Primary Subject Heading:	Smoking and tobacco
Secondary Subject Heading:	Health economics, Epidemiology, Health policy
Keywords:	HEALTH ECONOMICS, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH, STATISTICS & RESEARCH METHODS

SCHOLARONE™
Manuscripts

only

The Costs of Smoking and Secondhand Smoke Exposure in Taiwan

Hai-Yen Sung PhD¹, Li-Chuan Chang MS², Yu-Wen Wen PhD³, Yi-Wen Tsai PhD²

¹ Institute for Health & Aging, University of California, San Francisco, USA

² Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan

³ Clinical Informatics and Medical Statistics Research Center, Chang Gung University, Tao-Yuan, Taiwan

Corresponding Author: Hai-Yen Sung, PhD, Institute for Health & Aging, School of Nursing, University of California at San Francisco, 3333 California Street, Suite 340, San Francisco, CA 94118. Telephone: 415-502-4697; Fax: 415-476-3915; Email: Hai-Yen.Sung@ucsf.edu

Keywords: cost, smoking, secondhand smoke, smoking-attributable fraction, Taiwan

Word Count: 3963 words (max: 4000 words)

ABSTRACT

Objectives: To assess the costs of the health effects of cigarette smoking and secondhand smoke (SHS) exposure to society.

Design: Prevalence-based, disease-specific cost of illness study. We used an epidemiological population-attributable risk method to determine the costs that can be attributed to smoking and SHS exposure.

Setting: Taiwan.

Participants: All adult population aged 35 and older.

Primary outcome measures: Direct costs of healthcare expenditures spent for treating tobacco-related diseases, indirect mortality costs measured by the value of lost productivity due to tobacco-related premature deaths, and indirect morbidity costs measured by the value of time lost from work due to tobacco-related illness.

Results: In 2010, direct costs of smoking and SHS exposure amounted to \$828 million, accounting for 3.4% of Taiwan's total personal healthcare expenditures. Smoking and SHS exposure also contributed to 15,503 premature deaths — corresponding to a loss of 284,014 years of life and \$818 million in productivity — and \$22 million in indirect morbidity costs. These direct and indirect costs totaled \$1,668 million, representing 0.4% of Taiwan's gross domestic product (GDP) and averaging about \$700 per adult smoker. The share of the total costs was greater from active smoking (93%) than SHS exposure (7%), and greater for men (92%) than women (8%).

1
2
3
4
5 **Conclusions:** Smoking and SHS exposure impose a huge financial loss. Sustained tobacco
6
7 control efforts to encourage people to quit smoking, prevent smoking uptake by children and
8
9 young adults, and protect all people from SHS exposure are needed.
10
11
12
13
14
15
16
17
18

19 **Strengths and limitations of this study**

- 20
21 • Little is known about the economic costs of secondhand smoke (SHS) exposure in East
22
23 Asian countries. This is the first study to assess the health effects of smoking by taking into
24
25 account the economic impact of SHS exposure in Taiwan.
26
27
- 28
29 • This study provides evidence on the economic effect of the recent reduction in smoking
30
31 prevalence and SHS exposure on healthcare costs and productivity losses to the Taiwan society,
32
33 as a result of implementing a comprehensive tobacco control program in 2009.
34
35
- 36
37 • Only adults aged 35 and older were included in the study.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

East Asia is the world's largest tobacco epidemic region, consuming nearly half of total global cigarette consumption.[1] Although all East Asian countries ratified the WHO Framework Convention on Tobacco Control (FCTC) in 2004 or 2015, a recent assessment study [2] revealed that the majority of countries in East Asia lagged behind in implementing the FCTC recommended tobacco control programs according to WHO's MPOWER (Monitoring, Protect, Offer, Warn, Enforcement and Raise) criteria.[3] As of 2010, 37–53% of adult men in East Asia were current smokers and more than 46% of men were exposed to passive smoking at workplaces.[2] To enhance the incentives to implement the promises of the ratified FCTC to reduce the tobacco epidemic in East Asia, update evidence on the economic costs due to active and passive smoking-caused illness, disability, and premature mortality in this region is imperative.

Taiwan is regarded as a model in East Asia in tobacco control.[2] During 1960s and 1970s, smoking prevalence among Taiwanese aged 35 and above exceeded 75% for men and 8–12% for women. In 1987, Taiwan's cigarette market was forced to open to foreign brands, leading to a 6% jump in adult male smoking and a 13% jump in youth smoking within three years. As a consequence, the government launched a series of tobacco control initiatives such as school-based anti-smoking programs and the 1997 Tobacco Hazards Prevention Act through

1
2
3
4 which indoor places became partially smoke-free.[4] In 2002, the government levied tobacco
5
6
7 taxes of NT\$5 per pack and started the Outpatient Smoking Cessation Services.[5] During the
8
9
10 period of 1990-2005, smoking prevalence among men aged 18 and older had declined from
11
12
13 59.4% to 40.0%.[6] Taiwan's Legislature ratified the WHO FCTC in 2005. Based on the FCTC
14
15
16 recommendations,[7] an amendment to the Tobacco Hazards Prevention Act went into effect in
17
18
19 2009 (hereafter called the 2009 Act) to strengthen tobacco control measures by adding graphic
20
21
22 warning labels on cigarette packages, extending smoke-free areas to almost all enclosed
23
24
25 workplaces and public places, completely banning tobacco advertisements, promotion and
26
27
28 sponsorship, as well as increasing tobacco taxes.
29
30
31

32 As a result of the 2009 Act, smoking prevalence among men aged 18 and older in Taiwan
33
34
35 further decreased from 40.0% to 33.5% and exposure to passive smoking in workplaces
36
37
38 decreased substantially from 33.2% to 18.2% between 2005 and 2011.[6, 8] Given this sizeable
39
40
41 reduction in active and passive smoking, it is policy relevant to assess the current level of the
42
43
44 costs of active and passive smoking-attributable illness, disability, and premature mortality, and
45
46
47 to determine whether or not these costs have decreased.
48
49

50 Two previous studies estimated the cost of smoking in Taiwan in 2001. Using a
51
52
53 prevalence-based approach, Yang et al. estimated that smoking contributed to US\$398 million in
54
55
56 excess medical expenditures and US\$1,390 million in productivity loss from premature death
57
58
59
60

1
2
3
4 among people aged 35 and older.[9] Using an incidence-based approach, Chung et al.[10]
5
6
7 estimated that the present value of lifetime smoking-attributable medical costs among people
8
9
10 aged 35 and older ranged from \$291-\$336 million depending on discount rate. There has been no
11
12
13 study to update these cost estimates in Taiwan since 2001. Furthermore, none of studies on the
14
15
16 cost of smoking in Taiwan and few of those in the literature have included any costs attributed to
17
18
19 passive smoking, also known as secondhand smoke (SHS).
20
21

22
23 The main objective of this study is to assess the costs of the health effects of cigarette
24
25
26 smoking and SHS exposure in Taiwan in 2010. This is the first attempt to quantify the economic
27
28
29 costs of SHS exposure in Taiwan. This study will also provide an evaluation on the hypothesis
30
31
32 that implementation of the 2009 Act was associated with decreases in economic costs of smoking
33
34
35 and SHS exposure. Because of the similarity in tobacco epidemic and culture among East Asian
36
37
38 countries, the findings of this study can be served as a valuable reference for understanding the
39
40
41 economic benefits of tobacco control programs in the region.
42
43
44
45
46

47 **METHODS**

48
49
50 We considered three components of costs: direct costs of healthcare expenditures spent for
51
52
53 treating tobacco-related diseases, indirect mortality costs measured by the value of lost
54
55
56 productivity due to premature death, and indirect morbidity costs measured by the value of time
57
58
59
60

1
2
3
4 lost from work due to tobacco-related illness. Prevalence-based, disease-specific cost-of-illness
5
6
7 approach [11] was used to estimate the healthcare expenditures, workloss days, and deaths due to
8
9
10 smoking-related diseases in 2010. We used an epidemiological population-attributable risk
11
12
13 method [12] to determine the smoking-attributable fraction (SAF), which measures the
14
15
16 proportion of expenditures, workloss days, or deaths that can be attributed to smoking, and
17
18
19 applied it to the total measure. A SHS-attributable fraction (SAF^{SHS}) was estimated in a similar
20
21
22 manner. Our analyses focused on adults aged 35 years and older.
23
24

25 26 **Data sources**

27
28
29 Population-based data from the annual Adult Smoking Behavior Survey (ASBS) were used to
30
31
32 determine the prevalence of smoking and SHS exposure. The ASBS is a telephone interview
33
34
35 survey collecting information on individual's demographic characteristics, cigarette smoking and
36
37
38 quitting behavior, and SHS exposure from a nationally representative sample (around 16,000 per
39
40
41 year) of non-institutionalized population aged 18 and older in Taiwan. Disease-specific inpatient
42
43
44 and outpatient expenditures, and number of hospital inpatient days were obtained from the 2010
45
46
47 National Health Insurance (NHI) claims database. Taiwan's NHI, launched in 1995, is a
48
49
50 mandatory single-payer social health insurance system administered by the government that
51
52
53 provides universal healthcare coverage to virtually all citizens in Taiwan.
54
55
56
57
58
59
60

1
2
3
4 Population data came from the 2010 Population Census,[13] number of deaths for each
5
6
7 disease from the 2010 Statistics of Causes of Death,[14] and life expectancy by age and gender
8
9
10 from the 2010 life tables.[15] The age- and gender-specific employment rates and monthly
11
12
13 earnings were obtained from the 2010 Report on the Manpower Utilization Survey.[16]
14
15

16 **Smoking-related and SHS-associated diseases**

17
18
19 We included 19 smoking-related diseases which showed significant association between cigarette
20
21
22 smoking and mortality risk according to two large epidemiological studies conducted by Wen
23
24
25 and colleagues in Taiwan.[17, 18] We considered 6 SHS-associated diseases: lung cancer,
26
27
28 ischemic heart disease, cerebrovascular disease, chronic obstructive pulmonary disease, asthma,
29
30
31 and breast cancer, and 3 SHS-associated causes of death: lung cancer, ischemic heart disease, and
32
33
34 cerebrovascular disease as reported by the California Environmental Protection Agency (EPA)
35
36
37 [19] and World Health Organization (WHO).[20, 21] Details of these diseases and their diagnosis
38
39
40 codes are listed in Table 1.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Smoking-related disease, secondhand smoke (SHS)-associated disease and cause of death, and relative risk (RR) by disease and gender, Taiwan

Disease (ICD-9 code)	RR of Smoking-related death				RR of SHS-associated disease		RR of SHS-associated death	
	Male		Female		Male	Female	Male	Female
	CS	FS	CS	FS				
SMOKING-RELATED CAUSE OF DEATH								
All causes (001–998)	1.55	1.33	1.89	1.33				
Cancer								
Lip/oral cavity/pharynx (140–149)	2.60	1.96	–	–				
Esophagus (150)	3.18	2.31	15.57	6.40				
Stomach (151)	1.68	1.41	–	–				
Rectum (154)	2.06	1.64	–	–				
Liver/gallbladder/bile ducts (155–159)	1.46	1.28	5.03	2.49				
Lung (162) ^a	2.73	2.04	3.36	1.88	1.29	1.29	1.29	1.29
Cervix uteri (180)	–	–	5.78	2.77				
Cardiovascular disease								
Rheumatic HD (390–398)	–	–	9.43	4.13				
Ischemic HD (410–414) ^a	2.06	1.64	3.58	1.96	1.49	1.49	1.23	1.23
Cardiac arrest and other HD (420–429)	1.60	1.36	–	–				
Cerebrovascular disease (430–438) ^a	1.65	1.39	–	–	1.82	1.82	1.65	1.65
Respiratory disease								
Chronic bronchitis (491)	3.13	2.28	–	–				
Asthma (493) ^b	–	–	7.12	3.27	1.97	1.97		
Chronic Airway Obstruction (496)	2.65	1.99	–	–				
Digestive system disease								
Peptic ulcer, GI hemorrhage (531–535)	3.00	2.20	22.28	8.89				
Liver cirrhosis (571)	2.01	1.61	–	–				
Other smoking-related disease								
Diabetes mellitus (250)	1.51	1.31	–	–				
Kidney diseases (580–589)	2.23	1.74	–	–				
Accidents (800–949)	1.66	1.40	–	–				
OTHER SHS-ASSOCIATED DISEASE								
COPD (490–492, 496)					1.55	1.55		
Breast cancer (174) ^c					–	1.68		

Note. CS=current smoker; FS=former smoker; HD=heart disease; GI=gastrointestinal; COPD=chronic obstructive pulmonary disease.

^aAlso a SHS-associated disease and SHS-associated cause of death. ^bAlso a SHS-associated disease.

^cOnly among premenopausal women younger than age 50.

Smoking-attributable fraction (SAF) and SHS-attributable fraction (SAF^{SHS})

We calculated the SAF for each component of costs by disease, gender, and age group (35-49, 50-64, and ≥ 65 years). Based on two fundamental data elements: smoking prevalence and relative risk (RR) of *disease-specific death* for smoking, the SAF for death measures can be calculated using the following epidemiological formula: [11, 12]

$$SAF_{ijk} = \frac{P_{jk}^C (RR_{ij}^C - 1)}{P_{jk}^N + P_{jk}^C \times RR_{ij}^C + P_{jk}^F \times RR_{ij}^F} + \frac{P_{jk}^F (RR_{ij}^F - 1)}{P_{jk}^N + P_{jk}^C \times RR_{ij}^C + P_{jk}^F \times RR_{ij}^F} \quad (1)$$

where P^N , P^C , and P^F denote the prevalence of never, current, and former smokers, respectively;

RR^F denotes the RR of *disease-specific death* for former smokers in comparison to never smokers, and similarly RR^C denotes the RR of *disease-specific death* for current smokers; the

subscript i denotes disease, j denotes gender, and k denotes age group. The first term of

Equation (1) is the SAF for current smokers, and the second term is the SAF for former smokers.

Prevalence rates of current smokers, former smokers, and never smokers among adults aged 35 and older were obtained from the ASBS data. The RR of death for smokers is defined as the ratio of the death rate for smokers to that for never smokers. The RR^C came from the epidemiological studies by Wen and colleagues.[17, 18]; however, the RR^F was not available.

1
2
3
4 While the two previous cost-of-smoking studies in Taiwan assumed that the RR^F equals 1 and
5
6 thus the SAF for former smokers becomes zero (as illustrated by the second term of Equation (1)
7
8 above),[9,10] we used an interpolation approach to derive the RR^F . First, because Wen and
9
10 colleagues reported the RR of *all-cause death* for former smokers (RRA^F) and current smokers
11
12 (RRA^C),[17, 18] we could calculate the excess risk of *all-cause death* for former smokers over
13
14 never smokers as $(RRA^F - 1)$ and for current smokers over never smokers as $(RRA^C - 1)$.
15
16
17
18
19
20
21
22
23 Second, assuming the ratio between the excess risk of *disease-specific death* for former smokers
24
25 ($RR^F - 1$) and the excess risk of *disease-specific death* for current smokers ($RR^C - 1$) equals the
26
27 ratio between the excess risk of *all-cause death* for former smokers and the excess risk of
28
29 *all-cause death* for current smoker, we calculated $(RR^F - 1)$ by multiplying $(RR^C - 1)$ by the
30
31 ratio between $(RRA^F - 1)$ and $(RRA^C - 1)$. Finally, the relative risk RR^F equals the excess risk
32
33 $(RR^F - 1)$ plus 1.
34
35
36
37
38
39
40

41 To estimate the SAF for healthcare costs, we assumed the RRs of *disease-specific illness* for
42
43 current and former smokers are the same as those of *disease-specific death* for current and
44
45 former smokers because of data limitation.
46
47
48
49

50 Similarly, based on two fundamental data elements: prevalence of SHS exposure and
51
52 relative risk of *disease-specific death or illness* for SHS exposure, we calculated the SAF^{SHS}
53
54 among nonsmokers for each component of costs by disease, gender, and age group as:
55
56
57
58
59
60

$$SAF_{ijk}^{SHS} = \frac{P_{jk}^{SHS} (RR_{ij}^{SHS} - 1)}{P_{jk}^{SHS} (RR_{ij}^{SHS} - 1) + 1} \quad (2)$$

where P^{SHS} denotes the prevalence of SHS exposure among nonsmokers, and RR^{SHS} is the relative risk of *disease-specific death or illness* for exposed nonsmokers compared to unexposed nonsmokers.

Prevalence rates of SHS exposure among nonsmokers aged 35 and older were obtained from the ASBS data. Nonsmokers include never and former smokers. SHS exposed nonsmokers were those who either answered ‘yes’ to the question: ‘During the past week has anyone smoked in front of you at home?’ or who were employed and worked in indoor settings and answered ‘yes’ to the question: ‘During the past week has anyone smoked in front of you at your workplace?’ The RR^{SHS} of *disease-specific death* and the RR^{SHS} of *disease-specific illness* were obtained from published sources as reported by the California EPA [19] and WHO.[20, 21]

Table 1 shows the relative risk of disease-specific death and illness for current smokers, former smokers, and SHS exposure.

Direct costs

Expenditures paid by the NHI for inpatient hospitalizations and outpatient visits were included as

1
2
3
4 direct costs. Expenditures for prescribed medications during the hospitalizations or outpatient
5
6
7 visits were included in the respective inpatient or outpatient expenditure categories. Outpatient
8
9
10 visits comprised ambulatory care visits at outpatient or emergency departments of hospitals, and
11
12
13 those at western medicine clinics. The smoking-attributable inpatient or outpatient expenditure
14
15
16 for each subgroup stratified by disease, gender and age was calculated by multiplying the SAF
17
18
19 by the total annual inpatient or outpatient expenditures for that subgroup.
20
21

22
23 The SHS-attributable inpatient or outpatient expenditure for each disease was derived by
24
25 multiplying the SAF^{SHS} by the total annual inpatient or outpatient expenditures for that disease
26
27 among nonsmokers. Because the NHI claims database does not contain individual's smoking
28
29 status, it does not allow for distinguishing health expenditures for smokers from those for
30
31 nonsmokers. We determined the amount of total inpatient (similarly, outpatient) expenditures for
32
33 nonsmokers. We determined the amount of total inpatient (similarly, outpatient) expenditures for
34
35 nonsmokers. We determined the amount of total inpatient (similarly, outpatient) expenditures for
36
37 nonsmokers, INP^{NON} , using the following method as done by two recent studies.[20, 22]
38
39
40
41
42
43

$$44 \quad INP_{ijk}^{NON} = (INP_{ijk} - INP_{ijk} \times SAF_{ijk}^C) \times (1 - P_{jk}^C) \quad (3)$$

45
46
47
48
49

50 where INP is total annual inpatient expenditures among all individuals regardless of smoking
51
52 status, P^C is the prevalence of current smokers, and SAF^C is the smoking-attributable fraction for
53
54 current smokers as expressed by the first term of Equation (1).
55
56
57
58
59
60

Indirect mortality costs

For each subgroup stratified by gender and 5-year age group, we estimated the number of smoking-attributable deaths (SAD) for each disease by multiplying the SAF by the total number of deaths for that disease. The number of smoking-attributable years of potential life lost (YPLLs) was estimated by the product of the SAD and life expectancy remaining at the age of death. Smoking-attributable mortality cost was estimated by the product of the SAD and the present value of lifetime earnings (PVLEs) expected at the age of death. The PVLEs were calculated by gender and 5-year age groups based on a human capital approach developed by Max and colleagues.[23] A discount rate of 3% was used to convert the earnings into its current worth. A growth rate of 4%, which was approximately the average annual growth rate of gross domestic product (GDP) in Taiwan during 2005–2009, was used to take into account the potential growth of future earnings.

We estimated the number of SHS-attributable deaths, YPLLs, and mortality costs following the same approach as described for active smoking-attributable indirect mortality measures except that the estimation only focused on nonsmokers. Total number of deaths among nonsmokers was determined using the similar method as described for Equation (3).

Indirect morbidity costs

We defined smoking-attributable indirect morbidity cost as the value of time lost from work due

1
2
3
4 to active or passive smoking-caused illness. The lost time from work is commonly measured by
5
6
7 the number of workloss days;^[23, 24] however, because the data on workloss days by disease
8
9
10 were not available, we used inpatient days as a proxy. The smoking-attributable indirect
11
12
13 morbidity cost for each subgroup stratified by disease, gender and age was calculated by the
14
15
16 product of the SAF, total annual inpatient days for that group, the proportion of the population
17
18
19 currently employed, and daily earnings among employed persons.
20
21

22
23 Likewise, the SHS-attributable indirect morbidity cost was estimated by multiplying the
24
25
26 SAF^{SHS} by total annual inpatient days among nonsmokers, employment rate, and daily earnings.
27
28
29 Total number of inpatient days among nonsmokers was determined using the similar method as
30
31
32 described for Equations (3).
33
34

35 **Sensitivity analysis**

36
37
38 To evaluate whether or not implementation of the 2009 Act in Taiwan was associated with
39
40
41 decreases in active and passive smoking-attributable costs, we simulated what would be the cost
42
43
44 estimates in 2010 by assuming two scenarios: smoking prevalence and SHS exposure rates
45
46
47 remained at the same levels as in 2008, and smoking prevalence and SHS exposure rates were at
48
49
50 the mean value of the 2008 and 2010 levels. We also performed sensitivity analyses to see how
51
52
53 sensitive our cost estimates are to different assumptions about the RR values and productivity
54
55
56 growth rates.
57
58

RESULTS

In 2010, the total population of Taiwan was 23.2 million, with 12.4 million being adults aged 35

and older. The prevalence and SHS exposure rates among adults in 2008 and 2010 are shown in

Table 2. Smoking prevalence rates among men were about 10 times as high as those among

women: 33.9% versus 3.8% for current smoking, and 15.7% versus 1.5% for former smoking.

The SHS exposure rates among nonsmokers were similar between men and women. From 2008

to 2010, the current smoking prevalence among men decreased by nearly 10% and SHS exposure

among both genders decreased by 13%.

Table 2. Prevalence (%) of smoking and secondhand smoke (SHS) exposure by gender and age among adults aged 35 and older: Taiwan, 2008, 2010

	2008 ^a			2010 ^a		
	Smoking		SHS exposure ^b	Smoking		SHS exposure ^b
	CS	FS		CS	FS	
Total	21.6	7.8	28.3	19.2	8.8	24.7
Male	37.5	14.0	28.2	33.9	15.7	24.1
35-49	47.6	15.2	30.0	43.9	16.7	24.6
50-64	37.4	18.7	30.0	31.5	23.6	22.4
65+	29.1	26.8	17.0	19.5	30.1	12.9
Female	4.8	1.2	28.3	3.8	1.5	25.2
35-49	5.9	1.1	33.0	4.8	1.7	29.5
50-64	1.6	1.0	25.8	2.0	1.1	21.5
65+	1.9	1.0	13.8	1.3	1.0	13.2

Note. CS=current smoker; FS=former smoker.

^a Source: Adult Smoking Behavior Survey in Taiwan.

^b Percentage of nonsmokers who are exposed to secondhand smoke.

1
2
3
4 Table 3 shows the deaths and years of potential life lost attributed to smoking and SHS
5
6
7 exposure by cause of death and gender. The three leading causes of smoking-attributable deaths
8
9
10 among men were lung cancer, ischemic heart disease, and chronic airway obstruction, and
11
12 among women were cancers of liver/gallbladder/bile ducts, lung cancer, and ischemic heart
13
14 disease. The leading cause of SHS-associated deaths was stroke for both genders. There was a
15
16 substantial gender difference in the number of active smoking-attributable deaths — 13,744 for
17
18 men and 615 for women. SHS exposure almost equally affected both genders by contributing to
19
20 588 deaths among men and 556 deaths among women. They totaled 15,503 deaths, which
21
22 comprised about 20% of the total 19-cause deaths (77,953) among persons aged 35+ and 11% of
23
24 the total all-cause deaths (144,709) among persons aged 0+. The total smoking and SHS
25
26 attributable deaths were responsible for 284,014 years of potential life lost, averaging 18.3 years
27
28 per death.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Smoking-Attributable Mortality (SAM) and Smoking-Attributable Years of Potential Life Lost (SAYPLL) by Cause of Death and Gender among Adults Aged 35 and Older: Taiwan, 2010

Cause of death	Male		Female	
	SAM	SAYPLL	SAM	SAYPLL
SMOKING-RELATED DEATH	13,744	252,954	615	12,244
Cancers				
Lip/oral cavity/pharynx	1,135	29,214	0	0
Esophagus	715	17,356	24	493
Stomach	310	5,102	0	0
Rectum	250	4,397	0	0
Liver/gallbladder/bile ducts	920	19,031	181	3,682
Lung	2,198	34,801	129	2,988
Cervix uteri	0	0	72	2,010
Cardiovascular diseases				
Rheumatic HD	0	0	11	212
Ischemic HD	1,467	23,279	124	1,802
Cardiac arrest and other HD	816	14,119	0	0
Cerebrovascular disease	1,225	19,805	0	0
Respiratory diseases				
Chronic bronchitis	47	518	0	0
Asthma	0	0	24	366
Chronic Airway Obstruction	1,253	12,928	0	0
Digestive system diseases				
Peptic ulcer, GI hemorrhage	160	2,350	51	689
Liver cirrhosis	1,065	28,538	0	0
Other diseases				
Diabetes mellitus	689	11,477	0	0
Kidney disease	677	9,831	0	0
Accidents	817	20,207	0	0
SHS-ASSOCIATED DATH	588	9,407	556	9,409
Lung cancer	131	2,078	117	2,584
Ischemic HD	104	1,652	86	1,222
Cerebrovascular disease	353	5,677	354	5,603
TOTAL	14,332	262,361	1,172	21,653

Note. HD=heart disease; GI=gastrointestinal; SHS=secondhand smoke.

1
2
3
4 Table 4 shows the total direct and indirect costs attributed to smoking and SHS exposure by
5
6
7 gender, age, and disease. The total economic costs of smoking and SHS exposure in 2010
8
9
10 amounted to 1,668 million, including \$828 million (50%) in direct costs, \$818 million (49%) in
11
12
13 indirect mortality costs, and \$22 (1%) million in indirect morbidity costs. The share of the total
14
15
16 costs was greater from active smoking (93%) than SHS exposure (7%), and greater for men
17
18
19 (92%) than women (8%). The total economic costs averaged \$72 per Taiwanese aged 0+ and
20
21
22 \$701 per smoker aged 35+. Based on Taiwan's total cigarette consumption of 1,894 million
23
24
25 packs in 2010, the total economic costs averaged \$0.88 per pack, about 43% the 2010 average
26
27
28 retail price of cigarettes (NT\$65 or US\$2.05).[13]
29
30
31

32 Of the \$828 million in direct healthcare costs, \$104 million was spent for treating ischemic
33
34
35 heart disease, \$94 million for stroke, and \$53 million for lung cancer. Outpatient expenditures
36
37
38 amounted to \$520 million (63%) while inpatient expenditures were \$308 million (37%). Among
39
40
41 the \$22 million in indirect morbidity costs, \$18.7 million was due to active smoking and \$3.4
42
43
44 million was due to SHS exposure. The \$818 million in mortality costs averaged \$52,777 per
45
46
47 death among the 15,503 premature deaths caused by smoking or SHS exposure.
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4. Total Economic Costs of Smoking and Secondhand Smoke (SHS) Exposure by Component of Costs, Gender, Age, and Disease for Adults Aged 35 and Older: Taiwan, 2010 (Unit: US\$1,000)

	Direct costs			Indirect costs		Total economic costs
	Inpatient	Outpatient	Subtotal	Morbidity cost	Mortality cost	
Smoking	268,941	473,003	741,943	18,669	782,595	1,543,208
SHS exposure	39,179	46,894	86,073	3,407	35,610	125,090
Male	274,288	467,438	741,726	18,932	781,654	1,542,312
Female	33,832	52,458	86,290	3,144	36,551	125,985
35-49	61,319	114,908	176,228	10,797	462,239	649,264
50-64	106,579	204,427	311,006	9,601	260,569	581,176
65+	140,222	200,561	340,783	1,678	73,801	416,262
Lung cancer	21,191	31,552	52,743	1,249	86,729	140,721
Ischemic HD	66,157	38,128	104,285	1,615	62,728	168,628
Cerebrovascular	46,055	48,275	94,330	2,943	71,882	169,155
Other diseases ^a	174,717	401,942	576,659	16,270	596,866	1,189,795
Total	308,120	519,896	828,016	22,076	818,205	1,668,298

Note. HD=heart disease. Exchange rate of the Taiwanese Dollar against US\$ = 31.642 in 2010.

^a “Other” includes all the rest of smoking or SHS related diseases.

Sensitivity analysis

Table 5 shows that if the prevalence rates of smoking and SHS exposure in 2010 had remained at the same levels as in 2008, the toll of active and passive smoking-attributable losses would have been greater by additional 1,537 deaths and \$107 million in total economic cost. If the prevalence rates of smoking and SHS exposure were at the mean values of the 2009 and 2010 levels, there would have additional 855 deaths and \$59 million loss in total economic cost.

If we assumed the annual growth rate of productivity was 6% instead of 4%, total economic costs would be \$177 million higher. If we used the RR values for those smoking-related diseases reported by the widely cited American study,[24,25] our estimates of active and passive smoking- attributable premature deaths and total economic costs would increase by 6,984 deaths and \$506 million.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 5. Sensitivity Analysis of the Smoking and Secondhand Smoke (SHS) Attributable Mortality (SAM), Direct Healthcare Costs, and Total Economic Costs: Taiwan, 2010

	SAM		Direct costs		Total economic costs	
	No.	% of all deaths*	Amount (US\$ million)	% of NHE	Amount (US\$ million)	% of GDP
MAIN ANALYSIS	15,503	10.71	828	3.38	1,668	0.39
SENSITIVE ANALYSIS						
1. Smoking & SHS exposure prevalence						
Assume the levels in 2008	17,040	11.78	894	3.65	1,775	0.41
Assume the mean levels in 2008 & 2010	16,358	11.30	865	3.53	1,727	0.40
Assume the levels in 2001 ^a	18,868	13.04	971	3.96	1,903	0.44
2. Growth rate in productivity						
Assume 6% instead of 4%	15,503	10.71	828	3.38	1,845	0.43
3. Relative risk						
Assume RRs for former smokers = 1	11,088	7.66	629	2.57	1,322	0.31
Assume published RRs in the US ^b	22,487	15.54	1,042	4.25	2,174	0.51

Note. NHE=National personal healthcare expenditure (US\$24.5 billion in 2010); GDP=Gross Domestic Product (US\$430.1 billion in 2010). Exchange rate of the Taiwanese Dollar against US\$ = 31.642 in 2010.

* In 2010, the number of all-cause deaths among persons of all ages was 144,709.

^a For SHS exposure, because data on 2001 rates were available, we used the 2008 SHS exposure rates as a proxy.

^b See Table 12.1 in the 2014 US Surgeon General Report.[25]

DISCUSSION

The direct costs of smoking and SHS exposure for 2010 in Taiwan was \$828 million, accounting for 3.4% of total personal healthcare expenditures in the nation. Smoking and SHS exposure also led to 15,503 premature deaths, 284,014 years of potential life lost, \$818 million in indirect costs of productivity losses due to premature deaths, and \$22 million in indirect costs of time lost from work due to tobacco-related illness. These costs totaled \$1,668 million, representing 0.4% of Taiwan's gross domestic product (GDP) and averaging about \$700 per adult smoker.

The proportion of the total costs of smoking and SHS exposure to GDP in Taiwan is smaller than those estimated for other East Asia countries, such as 0.7% for China,[26] and 0.6%-0.8% for South Korea.[27] One possible explanation is because of relatively lower smoking rates in Taiwan. Another explanation may be the underestimation of our direct cost estimates which were based on the NHI claims database. The NHI database only includes health expenditures paid by the NHI, but not copayments or out-of-pocket payments that were spent on non-NHI covered health services such as orthodontics, long-term care, and nursing home care. In 2010, the NHI expenditures only comprised 57% of Taiwan's personal health expenditures.[28] Furthermore, due to limited data accessibility, we only included the NHI spending on inpatient care and Western medicine outpatient care. Other NHI covered health services such as Chinese medicine outpatient care accounted for 16% of the NHI expenditures in 2010.[28] If copayments,

1
2
3
4 out-of-pocket, and other NHI covered health expenditures are counted, our direct cost estimate
5
6
7 could be considerably larger than \$828 million.
8
9

10 A previous study in Taiwan [9] also included the same 19 smoking-related diseases and
11
12 used the same data source for relative risks. They estimated that active smoking caused 233,223
13
14 years of potential life lost (YPLLs) and \$467 million (after converting into 2010 constant dollars)
15
16 in direct healthcare costs in 2001. Our corresponding estimates in 2010 were 284,014 years and
17
18 \$818 million. These larger estimates seem contrary to the fact that smoking prevalence among
19
20 adults aged 35 and older had decreased substantially among men from 48.0% to 33.9% and
21
22 among women from 4.7% to 3.8% during 2001–2010. However, there is a caveat. Yang et al.[9]
23
24 assumed the relative risk of disease-specific death for former smokers equal to 1 and thus
25
26 assumed the smoking-attributable mortality and healthcare costs for former smokers were zero.
27
28 If we made the same assumption while holding all other parameters constant, our 2010 estimates
29
30 for YPLLs and direct healthcare costs would become 197,887 years and \$544 million. The new
31
32 2010 estimate for YPLLs is 15% smaller than the 2001 estimate,[9] which is consistent with the
33
34 declining smoking prevalence trend. The new 2010 estimate for smoking-attributable direct costs
35
36 is 16% larger than the 2001 estimate,[9] which could occur because Taiwan's personal health
37
38 expenditures rose by almost 40% in real term during 2001-2010.[28]
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 This study indicates that Taiwan's National Health Insurance spent \$828 million — 6% of
5
6
7 their budget — in 2010 to cover the excess healthcare expenditures caused by smoking and SHS
8
9
10 exposure. These costs were borne by all Taiwan residents including never smokers who paid for
11
12 insurance premium. Increasing cigarette taxes will help to offset the external costs of smoking
13
14 imposed by smokers on others.
15
16
17

18
19 Tobacco control programs are costly, but the benefits of tobacco control programs are
20
21 substantial. Several recent studies have shown that the 2009 Act in Taiwan was associated with a
22
23 reduction in adolescent smoking [29] and SHS exposure,[8] and an increase in adult cessation
24
25 rates.[30] Assuming a half of the reduction in adult smoking prevalence and SHS exposure
26
27 during 2008–2010 was driven by the 2009 Act, our sensitivity analysis results show that there
28
29 was a saving in avoided smoking and SHS attributable financial losses by \$59 million a year in
30
31 2010 alone.
32
33
34
35
36
37
38
39

40
41 This study makes several contributions. First, we considered the economic impact of SHS
42
43 exposure among adults aged 35+. Our results indicated that the SHS-attributable medical costs,
44
45 indirect morbidity costs, and indirect mortality costs were not negligible — equaling 12%, 18%,
46
47 and 5% of the levels of the active smoking-attributable direct medical costs, indirect morbidity
48
49 costs, and indirect mortality costs, respectively. Thus, not including the impact of SHS exposure
50
51 would underestimate the true burden of smoking. Second, we took into consideration
52
53
54
55
56
57
58
59
60

1
2
3
4 smoking-attributable costs for former smokers. Former smokers often quit smoking because they
5
6
7 have developed smoking-related illness. Although the risks of heart attack and stroke falls
8
9
10 quickly within the first five years after quitting,[31] the risks of other tobacco-related diseases
11
12
13 for former smokers takes longer time to reverse. Therefore, assuming the RRs for former
14
15
16 smokers equal to 1 may underestimate the economic costs of smoking when the prevalence of
17
18
19 former smokers, especially recent quitters, is high.
20
21
22

23 This study has several limitations. First, we did not consider costs of SHS exposure among
24
25
26 children and young adults under age 35, and nor the costs due to health problems of newborns
27
28
29 caused by maternal smoking such as low birth weight.[31] Second, in estimating indirect
30
31
32 morbidity costs, we did not count opportunity costs of relatives or informal caregivers who took
33
34
35 care of patients with smoking-related diseases, and productivity losses due to smoking-caused
36
37
38 disability other than inpatient days. Third, we used the relative risk of death as a proxy for the
39
40
41 relative risk of illness to estimate the smoking-attributable healthcare costs. Fourth, we derived
42
43
44 the relative risk of disease-specific death for former smokers using an interpolation approach.
45
46
47 Future research is needed to more accurately quantify the relative risk of disease-specific
48
49
50 mortality for former smokers in Taiwan. Lastly, we evaluated the impact of the 2009 Act on
51
52
53 smoking-attributable costs based on sensitivity analyses. Further research is needed to determine
54
55
56
57
58
59
60

1
2
3
4 the marginal effect of the 2009 Act on smoking prevalence while controlling for other
5
6
7 confounding factors.
8
9

10 Although smoking prevalence and SHS exposure in Taiwan have declined in recent years,
11
12 they still impose a huge financial loss. Thus, sustained tobacco control efforts to encourage
13
14 people to quit smoking, prevent smoking uptake by children and young adults, and protect all
15
16
17 people from SHS exposure are needed.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Acknowledgments:** The authors are grateful for the comments provided by Professors Kung-Yee
5
6 Liang, Teh-wei Hu, Kenneth E Warner, and Frank J Chaloupka.
7

8
9 **Competing interests:** None

10
11 **Funding:** This study was funded by Health Promotion Administration, Ministry of Health and
12
13 Welfare, Taiwan (grant CCY 10009-102).
14

15
16 **Contributorship:** HYS laid out the analytical framework, supervised all the steps of data
17
18 analysis, and revised the manuscript critically for important intellectual content. YWW drafted
19
20 the manuscript particularly on the method parts and helped to review and interpret the results.
21
22 LCC helped obtain all the data and conducted the analyses for this study. YWT conceptualized
23
24 the research idea, obtained the funding, drafted the manuscript and helped interpret the
25
26 results. All authors reviewed and approved the final manuscript.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **REFERENCES**
5
6

- 7 1. Campaign for Tobacco-Free Kids. *The Global Cigarette Industry*. June 2013.
8
9
10 http://global.tobaccofreekids.org/files/pdfs/en/Global_Cigarette_Industry_pdf.pdf (accessed 1
11
12
13 March 2014)
14
15
16 2. Katanoda K, Jiang Y, Park S, et al. Tobacco control challenges in East Asia: proposals for
17
18 change in the world's largest epidemic region. *Tob Control* Published Online First: 19 April
19
20 2013 doi: 101136/tobaccocontrol-2012-050852.
21
22
23
24
25 3. World Health Organization. *Report on the Global Tobacco Epidemic, 2008: the MPOWER*
26
27
28 *Package*. Geneva; 2008.
29
30
31 4. Wen CP, Cheng TY, Eriksen MP, et al. The impact of the cigarette market opening in Taiwan.
32
33
34
35 *Tob Control* 2005;**14 Suppl 1**:i4-9.
36
37
38 5. Chang FC, Chung CH, Yu PT, et al. The impact of graphic cigarette warning labels and
39
40
41 smoke-free law on health awareness and thoughts of quitting in Taiwan. *Health Educ Res*
42
43
44 2011;**26**(2):179-91.
45
46
47 6. Ministry of Health and Welfare, Taiwan. *2012 Taiwan Tobacco Control Annual Report*.
48
49
50
51 Executive Yuan, Health Promotion Administration, Taipei; 2013.
52
53
54 7. World Health Organization. *Framework Convention on Tobacco Control*. Geneva; 2003.
55
56
57 8. Tsai YW, Chang LC, Sung HY, et al. The impact of smoke-free legislation on reducing
58
59
60

- 1
2
3
4 exposure to secondhand smoke: differences across gender and socioeconomic groups. *Tob*
5
6
7 *Control* Published Online First: 10 September 2013 doi:
8
9
10 101136/tobaccocontrol-2013-051004.
11
12
13 9. Yang MC, Fann CY, Wen CP, et al. Smoking attributable medical expenditures, years of
14
15 potential life lost, and the cost of premature death in Taiwan. *Tob Control* 2005;**14 Suppl**
16
17 **1:i62-70**.
18
19
20
21
22 10. Chung CW, Wang JD, Yu CF, et al. Lifetime medical expenditure and life expectancy lost
23
24 attributable to smoking through major smoking related diseases in Taiwan. *Tob Control*
25
26 2007;**16(6):394-9**.
27
28
29
30
31 11. Sung H-Y, Max W, Gajalakshmi V, et al., editors. *Economics of Tobacco Toolkit: Assessment*
32
33 *of the Economic Costs of Smoking*. Geneva: World Health Organization; 2011.
34
35
36
37 12. Lilienfeld AM, Lilienfeld DE. *Foundations of epidemiology*. 3rd ed. New York: Oxford
38
39 University Press, 1994.
40
41
42
43 13. Ministry of Interior, Taiwan. *2012 Statistical Yearbook of Interior*. Executive Yuan,
44
45 Department of Statistics; 2013. <http://sowf.moi.gov.tw/stat/year/list.htm> (accessed 15 August
46
47 2013)
48
49
50
51
52 14. Ministry of Health and Welfare, Taiwan. *2010 Statistics of Causes of Death*. Executive Yuan.
53
54 http://www.mohw.gov.tw/EN/Ministry/Statistic.aspx?f_list_no=474&fod_list_no=3480
55
56
57
58
59
60

(accessed 13 June 2013)

15. Ministry of the Interior, Taiwan. *2010 Abridged life table in Taiwan*. Executive Yuan.
<http://sowf.moi.gov.tw/stat/english/elife/elist.htm> (accessed 14 April 2013)
16. Directorate-General of Budget, Accounting and Statistics, Taiwan. *2010 Report on the Manpower Utilization Survey*. Executive Yuan.
<http://www.dgbas.gov.tw/lp.asp?ctNode=4987&CtUnit=1183&BaseDSD=7> (accessed 15 May 2013)
17. Wen CP, Tsai SP, Chen CJ, et al. Smoking attributable mortality for Taiwan and its projection to 2020 under different smoking scenarios. *Tob Control* 2005;**14** Suppl 1:i76-80.
18. Wen CP, Tsai SP, Chen CJ, et al. The mortality risks of smokers in Taiwan: Part I: cause-specific mortality. *Prev Med* 2004;**39**(3):528-35.
19. California Environmental Protection Agency. *Proposed Identification of Environmental Tobacco Smoke as a Toxic Air Contaminant*. Sacramento, CA: California Environmental Protection Agency, Office of Environmental Health Hazard Assessment; 2005.
20. Öberg M, Jaakkola MS, Woodward A, et al. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. *Lancet* 2011;**377**(9760):139-46.
21. Öberg M, Jaakkola M, Woodward A. *Second-Hand Smoke: Assessing the Environmental*

- 1
2
3
4 *Burden of Disease at National and Local Levels*. Geneva: World Health Organization; 2010.
5
6
7
8 22. Max W, Sung HY, Shi Y. Deaths from secondhand smoke exposure in the United States:
9
10 economic implications. *Am J Public Health*. 2012;102(11):2173-80.
11
12
13
14 23. Max W, Rice DP, Sung HY, et al. Valuing human life: estimating the present value of lifetime
15
16 earnings. <http://repositories.cdlib.org/ctcre/esarm/PVLE2000> (accessed 8 May 2013)
17
18
19
20 24. Centers for Disease Control and Prevention. *Adult SAMMEC: Smoking-Attributable*
21
22 *Mortality, Morbidity, and Economic Costs*. (Online software). Atlanta, GA: Centers for
23
24 Disease Control and Prevention. https://apps.nccd.cdc.gov/sammec/show_esaf_data.asp
25
26 (accessed 8 May 2013)
27
28
29
30
31
32 25. US Department of Health and Human Services. *The Health Consequences of Smoking: 50*
33
34 *Years of Progress. A Report of the Surgeon General*. Atlanta, GA: Centers for Disease
35
36 Control and Prevention, National Center for Chronic Disease Prevention and Health
37
38 Promotion, Office on Smoking and Health; 2014.
39
40
41
42
43
44 26. Yang L, Sung HY, Mao Z, et al. Economic costs attributable to smoking in China: update and
45
46 an 8-year comparison, 2000-2008. *Tob Control* 2011;**20**(4):266-72.
47
48
49
50
51 27. Kang HY, Kim HJ, Park TK, et al. Economic burden of smoking in Korea. *Tob Control*
52
53 2003;**12**(1):37-44.
54
55
56
57 28. Ministry of Health and Welfare, Taiwan. 2010 National Health Expenditure. Executive Yuan;
58
59
60

1
2
3
4 November 2011.
5
6

- 7
8 29. Huang SL, Lin IF, Chen CY, et al. Impact of tobacco control policies on adolescent smoking:
9
10 findings from the global youth tobacco survey in Taiwan. *Addiction* 2013;**108**(10):1829-35.
11
12
13 30. Chang FC, Sung HY, Zhu SH, et al. Impact of the 2009 Taiwan tobacco hazards prevention
14
15 act on smoking cessation. *Addiction* 2014;**109**(1):140-6.
16
17
18 31. US Department of Health and Human Services. *How Tobacco Smoke Causes Disease: The*
19
20 *Biology and Behavioral Basis for Smoking-Attributable Disease. A Report of the Surgeon*
21
22 *General*. Atlanta, GA: Centers for Disease Control and Prevention, National Center for
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.

CHEERS Checklist**Items to include when reporting economic evaluations of health interventions**

The **ISPOR CHEERS Task Force Report**, *Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluations Publication Guidelines Good Reporting Practices Task Force*, provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: <http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp>

Section/item	Item No	Recommendation	Reported on page No/line No
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, and describe the interventions compared.	page 1, line1
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	page 2
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions.	pp 4-5. p.5, para 2 & P. 6, para2
Methods			
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	p4, line 7
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	page 4, para 2
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	p4, para 3
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	N/A
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	p6, para 2 & p7 para 1
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	p14, para 1
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	p6 para 3, p7 para 1
Measurement of effectiveness	11a	<i>Single study-based estimates:</i> Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	N/A



1		11b	<i>Synthesis-based estimates:</i> Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.	N/A
2				
3				
4				
5	Measurement and	12	If applicable, describe the population and methods used to elicit preferences for outcomes.	
6	valuation of preference			
7	based outcomes			pp. 6-7
8	Estimating resources	13a	<i>Single study-based economic evaluation:</i> Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	pp. 10-15
9	and costs			
10		13b	<i>Model-based economic evaluation:</i> Describe approaches and data sources used to estimate resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	N/A
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23	Currency, price date,	14	Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate.	Tables 4-5
24	and conversion			
25				
26				
27				
28				
29	Choice of model	15	Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended.	p7 para 1 & p8
30				
31				
32				
33	Assumptions	16	Describe all structural or other assumptions underpinning the decision-analytical model.	p11 para 1-2
34				
35	Analytical methods	17	Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty.	7-8
36				
37				
38				
39				
40				p11 & p15 para 3
41				
42				
43	Results			
44	Study parameters	18	Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended.	Tables 1-2
45				
46				
47				
48				
49				
50	Incremental costs and	19	For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios.	N/A
51	outcomes			
52				
53				
54				
55	Characterising	20a	<i>Single study-based economic evaluation:</i> Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact	P22
56	uncertainty			
57				
58				
59				
60				



1		of methodological assumptions (such as discount rate, study perspective).	& Table 5
2			
3			
4	20b	<i>Model-based economic evaluation</i> : Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.	N/A
5			
6			
7	Characterising heterogeneity	21	
8		If applicable, report differences in costs, outcomes, or cost-effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	N/A
9			
10			
11			
12			
13			
14	Discussion		
15	Study findings, limitations, generalisability, and current knowledge	22	
16		Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.	pp. 24–25
17			
18			
19			
20	Other		
21	Source of funding	23	
22		Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	p29
23			
24	Conflicts of interest	24	
25		Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	p29
26			
27			
28			
29			
30			

For consistency, the CHEERS Statement checklist format is based on the format of the CONSORT statement checklist

The **ISPOR CHEERS Task Force Report** provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* link or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: <http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp>

The citation for the CHEERS Task Force Report is:

Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. *Value Health* 2013;16:231-50.

BMJ Open

The Costs of Smoking and Secondhand Smoke Exposure in Taiwan: A Prevalence-Based Annual Cost Approach

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005199.R1
Article Type:	Research
Date Submitted by the Author:	27-May-2014
Complete List of Authors:	Sung, Hai-Yen; University of California San Francisco, Institute for Health & Aging Chang, Li-Chuan; National Yang-Ming University, Institute of Health and Welfare Policy Wen, Yu-Wen; Chang Gung University, Clinical Informatics and Medical Statistics Research Center Tsai, Yi-Wen; National Yang-Ming University, Institute of Health and Welfare Policy
Primary Subject Heading:	Smoking and tobacco
Secondary Subject Heading:	Health economics, Epidemiology, Health policy
Keywords:	HEALTH ECONOMICS, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH, STATISTICS & RESEARCH METHODS

SCHOLARONE™
Manuscripts

Only

1
2
3
4
5 **The Costs of Smoking and Secondhand Smoke Exposure in Taiwan: A**
6
7 **Prevalence-Based Annual Cost Approach**
8
9

10
11 **Hai-Yen Sung PhD¹, Li-Chuan Chang MS², Yu-Wen Wen PhD³, Yi-Wen Tsai PhD²**
12
13

14
15
16
17
18 ¹ Institute for Health & Aging, University of California, San Francisco, USA
19

20
21 ² Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan
22

23
24 ³ Clinical Informatics and Medical Statistics Research Center, Chang Gung University, Tao-Yuan,
25
26
27 Taiwan
28

29
30
31
32
33 **Corresponding Author:** Hai-Yen Sung, PhD, Institute for Health & Aging, School of Nursing,
34
35
36 University of California at San Francisco, 3333 California Street, Suite 340, San Francisco, CA
37
38
39 94118. Telephone: 415-502-4697; Fax: 415-476-3915; Email: Hai-Yen.Sung@ucsf.edu
40
41

42
43
44 **Keywords:** cost, smoking, secondhand smoke, smoking-attributable fraction, Taiwan
45
46

47
48
49 **Word Count:** 3963 words (max: 4000 words)
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: To assess the costs of the health effects of cigarette smoking and secondhand smoke (SHS) exposure to society.

Design: Prevalence-based, disease-specific cost-of-illness study. We used an epidemiological population-attributable risk method to determine the costs that can be attributed to smoking and SHS exposure.

Setting: Taiwan.

Participants: All adult population aged 35 and older.

Primary outcome measures: Direct costs of healthcare expenditures spent for treating tobacco-related diseases, indirect mortality costs measured by the value of lost productivity due to tobacco-related premature deaths, and indirect morbidity costs measured by the value of time lost from work due to tobacco-related illness.

Results: In 2010, direct costs of smoking and SHS exposure amounted to US\$828 million, accounting for 3.4% of Taiwan's total personal healthcare expenditures. Smoking and SHS exposure also contributed to 15,555 premature deaths — corresponding to a loss of 284,765 years of life and US\$820 million in productivity — and US\$22 million in indirect morbidity costs. These direct and indirect costs totaled US\$1,670 million, representing 0.4% of Taiwan's gross domestic product (GDP) and averaging about US\$720 per adult smoker. The share of the total costs was greater from active smoking (92%) than SHS exposure (8%), and greater for men (92%) than women (8%).

1
2
3
4
5 **Conclusions:** Smoking and SHS exposure impose a huge financial loss in Taiwan. Sustained
6
7 tobacco control efforts to encourage people to quit smoking, prevent smoking uptake by children
8
9 and young adults, and protect all people from SHS exposure are needed.
10
11
12
13
14
15
16
17
18

19 **Strengths and limitations of this study**

- 20
21 • Little is known about the economic costs of secondhand smoke (SHS) exposure in East
22
23 Asian countries. This is the first study to assess the health effects of smoking by taking into
24
25 account the economic impact of SHS exposure in Taiwan.
26
27
- 28
29 • This study provides evidence on the economic effect of the recent reduction in smoking
30
31 prevalence and SHS exposure on healthcare costs and productivity losses to the Taiwan society,
32
33 as a result of implementing a comprehensive tobacco control program in 2009.
34
35
- 36
37 • Only adults aged 35 and older were included in the study.
38
39
- 40
41 • The relative risks of healthcare cost for smokers are assumed to be the same as the relative
42
43 risks of death for smokers because of data limitation.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

East Asia is the world's largest tobacco epidemic region, consuming nearly half of total global cigarette consumption.[1] Although all East Asian countries ratified the WHO Framework Convention on Tobacco Control (FCTC) in 2004 or 2015, a recent assessment study [2] revealed that the majority of countries in East Asia lagged behind in implementing the FCTC recommended tobacco control programs according to WHO's MPOWER (Monitoring, Protect, Offer, Warn, Enforcement and Raise) criteria.[3] As of 2010, 37–53% of adult men in East Asia were current smokers and more than 46% of men were exposed to passive smoking at workplaces.[2] To enhance the incentives to implement the promises of the ratified FCTC to reduce the tobacco epidemic in East Asia, update evidence on the economic costs due to active and passive smoking-caused illness, disability, and premature mortality in this region is imperative.

Taiwan is regarded as a model in East Asia in tobacco control.[2] During 1960s and 1970s, smoking prevalence among Taiwanese aged 35 and above exceeded 75% for men and 8–12% for women.[4] In 1987, Taiwan's cigarette market was forced to open to foreign brands, leading to a 6% jump in adult male smoking and a 13% jump in youth smoking within three years.[4] As a consequence, the government launched a series of tobacco control initiatives such as school-based anti-smoking programs and the 1997 Tobacco Hazards Prevention Act through

1
2
3
4 which indoor workplaces and public places became partially smoke-free. [5] In 2002, the
5
6
7 government levied a tobacco tax amounting to five New Taiwan Dollars (NT\$) per pack and
8
9
10 started the Outpatient Smoking Cessation Services. [5] During the period of 1990-2005, smoking
11
12
13 prevalence among men aged 18 and older had declined from 59.4% to 40.0%. [5] Taiwan's
14
15
16 Legislature ratified the WHO FCTC in 2005. Based on the FCTC recommendations, [6] an
17
18
19 amendment to the Tobacco Hazards Prevention Act went into effect in 2009 (hereafter called the
20
21
22 2009 Act) to strengthen existing tobacco control measures by adding graphic warning labels on
23
24
25 cigarette packages, extending smoke-free areas to almost all enclosed workplaces and public
26
27
28 places, completely banning tobacco advertisements, promotion and sponsorship, as well as
29
30
31 increasing tobacco taxes.
32
33
34

35 As a result of the 2009 Act, smoking prevalence among men aged 18 and older in Taiwan
36
37
38 further decreased from 40.0% to 33.5% and exposure to passive smoking in workplaces
39
40
41 decreased substantially from 33.2% to 18.2% between 2005 and 2011. [5, 7] Given this sizeable
42
43
44 reduction in active and passive smoking, it is policy relevant to assess the current level of the
45
46
47 costs of active and passive smoking-attributable illness, disability, and premature mortality, and
48
49
50 to determine whether or not these costs have decreased.
51
52
53

54 Two previous studies estimated the cost of smoking in Taiwan. Using a prevalence-based
55
56
57 approach, Yang et al. estimated that in 2001 smoking contributed to US\$398 million in excess
58
59
60

1
2
3
4 medical expenditures and US\$1,390 million in productivity loss from premature death among
5
6
7 people aged 35 and older in Taiwan.[8] Using an incidence-based approach, Chung et al.[9]
8
9
10 estimated that the present value of lifetime smoking-attributable medical costs among people
11
12
13 aged 35 and older ranged from US\$291-\$336 million depending on discount rate for the year
14
15
16 2001 in Taiwan. There has been no study to update these cost estimates in Taiwan since 2001.
17
18
19 Furthermore, none of studies on the cost of smoking in Taiwan and few of those in the literature
20
21
22 have included any health costs attributed to passive smoking, also known as secondhand smoke
23
24
25 (SHS).
26
27

28
29 The main objective of this study is to assess the costs of the health effects of cigarette
30
31
32 smoking and SHS exposure in Taiwan in 2010. This is the first attempt to quantify the economic
33
34
35 costs of SHS exposure in Taiwan. This study will also provide an evaluation on the hypothesis
36
37
38 that implementation of the 2009 Act was associated with decreases in economic costs of smoking
39
40
41 and SHS exposure. Because of the similarity in tobacco epidemic and culture among East Asian
42
43
44 countries, the findings of this study can be served as a valuable reference for understanding the
45
46
47 economic benefits of tobacco control programs in the region.
48
49
50

51 52 53 **METHODS**

54
55
56 We considered three components of costs: direct costs of healthcare expenditures spent for
57
58
59

1
2
3
4 treating tobacco-related diseases, indirect mortality costs measured by the value of lost
5
6
7 productivity due to premature death, and indirect morbidity costs measured by the value of time
8
9
10 lost from work due to tobacco-related illness. Prevalence-based, disease-specific cost-of-illness
11
12 approach [10] was used to estimate the healthcare expenditures, workloss days, and deaths due to
13
14 smoking-related diseases in 2010. We used an epidemiological population-attributable risk
15
16
17 method [11] to determine the smoking-attributable fraction (SAF), which measures the
18
19
20 proportion of expenditures, workloss days, or deaths that can be attributed to smoking, and
21
22
23 applied it to the total measure. A SHS-attributable fraction (SAF^{SHS}) was estimated in a similar
24
25
26
27
28
29 manner. Our analyses focused on adults aged 35 years and older.
30

31 32 **Data sources**

33
34
35 Population-based data from the annual Adult Smoking Behavior Survey (ASBS) were used to
36
37
38 determine the prevalence of smoking and SHS exposure. The ASBS is a telephone interview
39
40
41 survey collecting information on individual's demographic characteristics, cigarette smoking and
42
43
44 quitting behavior, and SHS exposure from a nationally representative sample (around 16,000 per
45
46
47 year) of non-institutionalized population aged 18 and older in Taiwan. Disease-specific inpatient
48
49
50 and outpatient expenditures, and number of hospital inpatient days were obtained from the 2010
51
52
53 National Health Insurance (NHI) claims database. Taiwan's NHI, launched in 1995, is a
54
55
56
57
58
59
60

1
2
3
4 mandatory single-payer social health insurance system administered by the government that
5
6
7 provides universal healthcare coverage to virtually all citizens in Taiwan.
8
9

10 Population data came from the 2010 Population Census,[12] number of deaths for each
11
12 disease from the 2010 Statistics of Causes of Death,[13] and life expectancy by age and gender
13
14 from the 2010 life tables.[14] The age- and gender-specific employment rates and monthly
15
16 earnings were obtained from the 2010 Report on the Manpower Utilization Survey.[15]
17
18
19
20
21

22 **Smoking-related and SHS-associated diseases**

23
24
25 We included 19 smoking-related diseases which were identified to have a significant association
26
27 between cigarette smoking and mortality risk by two large epidemiological studies conducted in
28
29 Taiwan.[16, 17] We considered six SHS-associated diseases: lung cancer, ischemic heart disease,
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
disease, and asthma as reported by the California Environmental Protection Agency (EPA) [18]
and World Health Organization (WHO).[19, 20] Details of these diseases and their diagnosis
codes are listed in Table 1.

Table 1. Smoking-related disease, secondhand smoke (SHS)-associated disease and cause of death, and relative risk (RR) by disease and gender, Taiwan

Disease (ICD-9 code)	RR of Smoking-related death				RR of SHS-associated disease		RR of SHS-associated cause of death	
	Male		Female		Male	Female	Male	Female
	CS	FS	CS	FS				
SMOKING-RELATED CAUSE OF DEATH								
All causes (001–998)	1.55	1.33	1.89	1.33				
Cancer								
Lip/oral cavity/pharynx (140–149)	2.60	1.96	–	–				
Esophagus (150)	3.18	2.31	15.57	6.40				
Stomach (151)	1.68	1.41	–	–				
Rectum (154)	2.06	1.64	–	–				
Liver/gallbladder/bile ducts (155–159)	1.46	1.28	5.03	2.49				
Lung (162) ^a	2.73	2.04	3.36	1.88	1.29	1.29	1.29	1.29
Cervix uteri (180)	–	–	5.78	2.77				
Cardiovascular disease								
Rheumatic HD (390–398)	–	–	9.43	4.13				
Ischemic HD (410–414) ^a	2.06	1.64	3.58	1.96	1.49	1.49	1.23	1.23
Cardiac arrest and other HD (420–429)	1.60	1.36	–	–				
Cerebrovascular disease (430–438) ^a	1.65	1.39	–	–	1.82	1.82	1.65	1.65
Respiratory disease								
Chronic bronchitis (491)	3.13	2.28	–	–				
Asthma (493) ^a	–	–	7.12	3.27	1.97	1.97	1.97	1.97
Chronic Airway Obstruction (496)	2.65	1.99	–	–				
Digestive system disease								
Peptic ulcer, GI hemorrhage (531–535)	3.00	2.20	22.28	8.89				
Liver cirrhosis (571)	2.01	1.61	–	–				
Other smoking-related disease								
Diabetes mellitus (250)	1.51	1.31	–	–				
Kidney diseases (580–589)	2.23	1.74	–	–				
Accidents (800–949)	1.66	1.40	–	–				
OTHER SHS-ASSOCIATED DISEASE								
COPD (490–492, 496)					1.55	1.55		
Breast cancer (174) ^b					–	1.68		

Note. CS=current smoker; FS=former smoker; HD=heart disease; GI=gastrointestinal; COPD=chronic obstructive pulmonary disease.

^aAlso a SHS-associated disease and SHS-associated cause of death. ^bOnly among premenopausal women younger than age 50.

Smoking-attributable fraction (SAF) and SHS-attributable fraction (SAF^{SHS})

We calculated the SAF for each component of costs by disease, gender, and age group (35-49, 50-64, and ≥ 65 years). Based on two fundamental data elements: smoking prevalence and relative risk (RR) of *disease-specific death* for smoking, the SAF for death measures can be calculated using the following epidemiological formula: [10, 11]

$$SAF_{ijk} = \frac{P_{jk}^C (RR_{ij}^C - 1)}{P_{jk}^N + P_{jk}^C \times RR_{ij}^C + P_{jk}^F \times RR_{ij}^F} + \frac{P_{jk}^F (RR_{ij}^F - 1)}{P_{jk}^N + P_{jk}^C \times RR_{ij}^C + P_{jk}^F \times RR_{ij}^F} \quad (1)$$

where P^N , P^C , and P^F denote the prevalence of never, current, and former smokers, respectively; RR^C (or RR^F) denotes the RR of disease-specific death for current (or former) smokers in comparison to never smokers; the subscript i denotes disease, j denotes gender, and k denotes age group. Note that $(RR^C - 1)$ denotes the excess risk of disease-specific death for current smokers over never smokers, and similarly, $(RR^F - 1)$ denotes the excess risk of disease-specific death for former smokers over never smokers. The first term of Equation (1) is the SAF for current smokers, and the second term is the SAF for former smokers.

Prevalence rates of current smokers, former smokers, and never smokers among adults aged 35 and older were obtained from the ASBS data. The RR of death for smokers is defined as the

1
2
3
4 ratio of the death rate for smokers to that for never smokers. Given the huge body of scientific
5
6
7 evidence that smokers have a greater risk of mortality compared with never smokers, the RR
8
9
10 should be greater than 1 and the excess risk should be greater than zero. The disease-specific
11
12
13 relative risks for current smokers (RR^C) specific among Taiwanese adults were taken from the
14
15
16 two aforementioned epidemiological studies in Taiwan.[16, 17]; however, the disease-specific
17
18
19 relative risks for former smokers (RR^F) were not available in published sources. Instead of
20
21
22 adopting the assumption that the RR^F equal 1 and forcing the SAF for former smokers to
23
24
25 becomes zero as other studies have done,[8, 9] we derived a proxy measure for the RR^F based on
26
27
28 the assumption that the ratio between the excess risk for former smokers and the excess risk for
29
30
31 current smokers is the same for any disease-specific death and all-cause death. Fortunately, in the
32
33
34 same data sources which provided the disease-specific RR^C , the all-cause relative risk for current
35
36
37 smokers (RRA^C) and the all-cause relative risk for former smokers (RRA^F) were also
38
39
40 provided.[16, 17] Based on these relative risk data and our assumption, we estimated the
41
42
43 disease-specific relative risks for former smokers via the following calculation: $(RR^C - 1) \times$
44
45
46 $(RRA^F - 1) / (RRA^C - 1) + 1$.

47
48
49
50 To estimate the SAF for healthcare costs, we assumed the RRs of disease-specific
51
52
53 healthcare cost for current and former smokers are the same as those of disease-specific death for
54
55
56 current and former smokers because of data limitation.
57
58
59
60

1
2
3
4 Similarly, based on two fundamental data elements: prevalence of SHS exposure and
5
6
7 relative risk of disease-specific death or illness for SHS exposure, we calculated the SAF^{SHS}
8
9
10 among nonsmokers for each component of costs by disease, gender, and age group as:

$$SAF_{ijk}^{SHS} = \frac{P_{jk}^{SHS} (RR_{ij}^{SHS} - 1)}{P_{jk}^{SHS} (RR_{ij}^{SHS} - 1) + 1} \quad (2)$$

11
12
13
14
15
16
17
18
19
20
21
22
23
24 where P^{SHS} denotes the prevalence of SHS exposure among nonsmokers, and RR^{SHS} is the
25
26
27 relative risk of disease-specific death or illness for exposed nonsmokers compared to unexposed
28
29
30 nonsmokers.
31

32
33
34 Prevalence rates of SHS exposure among nonsmokers aged 35 and older were obtained
35
36
37 from the ASBS data. Nonsmokers include never and former smokers. SHS exposed nonsmokers
38
39
40 were either those who either answered 'yes' to the question: 'During the past week has anyone
41
42
43 smoked in front of you at home?' or those who were employed and worked in indoor settings
44
45
46 and answered 'yes' to the question: 'During the past week has anyone smoked in front of you at
47
48
49 your workplace?' The RR^{SHS} of disease-specific death and the RR^{SHS} of disease-specific illness
50
51
52 were obtained from published sources as reported by the California EPA [18] and WHO.[19, 20]
53
54

55 The relative risks for each disease and each cause of death for current smokers, former
56
57
58
59
60

1
2
3
4 smokers, and SHS exposure are shown in Table 1.
5
6

7 **Direct costs**

8
9
10 Expenditures paid by the NHI for inpatient hospitalizations and outpatient visits were included as
11
12 direct costs. Expenditures for prescribed medications during the hospitalizations or outpatient
13
14 visits were included in the respective inpatient or outpatient expenditure categories. Outpatient
15
16 visits were included in the respective inpatient or outpatient expenditure categories. Outpatient
17
18 visits comprised ambulatory care visits at outpatient or emergency departments of hospitals, and
19
20 those at western medicine clinics. The smoking-attributable inpatient or outpatient expenditure
21
22 for each subgroup stratified by disease, gender and age was calculated by multiplying the SAF
23
24 for each subgroup by the total annual inpatient or outpatient expenditures for that subgroup.
25
26
27
28
29
30
31

32 The SHS-attributable inpatient or outpatient expenditure for each disease was derived by
33
34 multiplying the SAF^{SHS} by the total annual inpatient or outpatient expenditures for that disease
35
36 among nonsmokers. Because the NHI claims database does not contain individual's smoking
37
38 status, it does not allow for distinguishing health expenditures for smokers from those for
39
40 nonsmokers. We determined the amount of total inpatient (similarly, outpatient) expenditures for
41
42 nonsmokers. We determined the amount of total inpatient (similarly, outpatient) expenditures for
43
44 nonsmokers, INP^{NON} , using the following method as used by two recent studies. [19, 21]
45
46
47
48
49
50
51
52

$$53 \quad INP_{ijk}^{NON} = (INP_{ijk} - INP_{ijk} \times SAF_{ijk}^C) \times (1 - P_{jk}^C) \quad (3)$$

54
55
56
57
58
59
60

1
2
3
4 where INP is total annual inpatient expenditures among all individuals regardless of smoking
5
6
7 status, P^C is the prevalence of current smokers, and SAF^C is the smoking-attributable fraction for
8
9
10 current smokers as expressed by the first term of Equation (1).
11

12 13 **Indirect mortality costs**

14
15
16 For each subgroup stratified by gender and 5-year age group, we estimated the number of
17
18
19 smoking-attributable deaths (SAD) for each disease by multiplying the SAF by the total number
20
21
22 of deaths for that disease. The number of smoking-attributable years of potential life lost (YPLLs)
23
24
25 was estimated by the product of the SAD and life expectancy remaining at the age of death.
26
27

28
29 Smoking-attributable mortality cost was estimated by the product of the SAD and the present
30
31
32 value of lifetime earnings (PVLEs) expected at the age of death. The PVLEs were calculated by
33
34
35 gender and 5-year age groups based on a human capital approach developed by Max and
36
37
38 colleagues.[22] A discount rate of 3% was used to convert the earnings into its current worth. A
39
40
41 growth rate of 4%, which was approximately the average annual growth rate of gross domestic
42
43
44 product (GDP) in Taiwan during 2005–2009, was used to take into account the potential growth
45
46
47 of future earnings.
48

49
50 We estimated the number of SHS-attributable deaths, YPLLs, and mortality costs following
51
52
53 the same approach as described for active smoking-attributable indirect mortality measures
54
55
56 except that the estimation only focused on nonsmokers. Total number of deaths among
57
58

1
2
3
4 nonsmokers was determined using the similar method as described for Equation (3).
5
6

7 **Indirect morbidity costs**

8

9
10 We defined smoking-attributable indirect morbidity cost as the value of time lost from work due
11
12 to active or passive smoking-caused illness. The lost time from work is commonly measured by
13
14 the number of workloss days;[23] however, because the data on workloss days by disease were
15
16 not available, we used inpatient days as a proxy. The smoking-attributable indirect morbidity cost
17
18 for each subgroup stratified by disease, gender and age was calculated by the product of the SAF,
19
20 total annual inpatient days for that group, the proportion of the population currently employed,
21
22 and daily earnings among employed persons.
23
24
25
26
27
28
29
30
31

32 Likewise, the SHS-attributable indirect morbidity cost was estimated by multiplying the
33
34 SAF^{SHS} by total annual inpatient days among nonsmokers, employment rate, and daily earnings.
35
36

37
38 Total number of inpatient days among nonsmokers was determined using the similar method as
39
40 described for Equations (3).
41
42
43

44 **Sensitivity analysis**

45

46
47 To evaluate whether or not implementation of the 2009 Act in Taiwan was associated with
48
49 decreases in active and passive smoking-attributable costs, we simulated what would be the cost
50
51 estimates in 2010 by assuming two scenarios: smoking prevalence and SHS exposure rates
52
53 remained at the same levels as in 2008, and smoking prevalence and SHS exposure rates were at
54
55
56
57
58
59
60

1
2
3
4 the mean value of the 2008 and 2010 levels. We also performed sensitivity analyses to see how
5
6
7 sensitive our cost estimates are to different assumptions about the RR values and productivity
8
9
10 growth rates.
11
12
13

14 15 16 17 **RESULTS**

18
19 In 2010, the total population of Taiwan was 23.2 million. Among the 12.4 million adults aged 35
20
21 and older, 2.3 million were current smokers. The smoking prevalence and SHS exposure rates by
22
23 gender and age in 2008 and 2010 are shown in Table 2. In 2010, smoking prevalence rates
24
25 among men were about 10 times as high as those among women: 33.9% versus 3.8% for current
26
27 smoking, and 15.7% versus 1.5% for former smoking. The SHS exposure rates among
28
29 nonsmokers were similar between men and women. From 2008 to 2010, the current smoking
30
31 prevalence among men decreased by nearly 10% and SHS exposure among both genders
32
33 decreased by 13%.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Prevalence (%) of smoking and secondhand smoke (SHS) exposure by gender and age among adults aged 35 and older: Taiwan, 2008 and 2010

	2008 ^a			2010 ^a		
	Smoking		SHS exposure ^b	Smoking		SHS exposure ^b
	CS	FS		CS	FS	
Total	21.6	7.8	28.3	19.2	8.8	24.7
Male	37.5	14.0	28.2	33.9	15.7	24.1
35-49	47.6	15.2	30.0	43.9	16.7	24.6
50-64	37.4	18.7	30.0	31.5	23.6	22.4
65+	29.1	26.8	17.0	19.5	30.1	12.9
Female	4.8	1.2	28.3	3.8	1.5	25.2
35-49	5.9	1.1	33.0	4.8	1.7	29.5
50-64	1.6	1.0	25.8	2.0	1.1	21.5
65+	1.9	1.0	13.8	1.3	1.0	13.2

Note. CS=current smoker; FS=former smoker.

^a Source: Adult Smoking Behavior Survey in Taiwan.

^b Percentage of nonsmokers who are exposed to secondhand smoke in the home or at the workplace.

1
2
3
4 Table 3 shows the deaths and years of potential life lost attributed to smoking and SHS
5
6
7 exposure by cause of death and gender. The three leading causes of smoking-attributable deaths
8
9
10 among men were lung cancer, ischemic heart disease, and chronic airway obstruction, and
11
12 among women were cancers of liver/gallbladder/bile ducts, lung cancer, and ischemic heart
13
14 disease. The leading cause of SHS-associated deaths was stroke for both genders. There was a
15
16 substantial gender difference in the number of active smoking-attributable deaths — 13,744 for
17
18 men and 615 for women. SHS exposure almost equally affected both genders by contributing to
19
20 613 deaths among men and 583 deaths among women. Smoking and SHS exposure contributed
21
22 to a total of 15,555 deaths, which comprised about 20% of the total 19-cause deaths (77,953)
23
24 among persons aged 35+ and 11% of the total all-cause deaths (144,709) among persons aged 0+.
25
26 They were responsible for 284,755 years of potential life lost, averaging 18.3 years per death.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Total Deaths, Smoking-Attributable Mortality (SAM), and Smoking-Attributable Years of Potential Life Lost (SAYPLL) by Cause of Death and Gender among Adults Aged 35 and Older: Taiwan, 2010

Cause of death	Male			Female		
	Death ^a	SAM	SAYPLL	Death ^a	SAM	SAYPLL
SMOKING-RELATED DEATH	49,563	13,744	252,954	28,390	615	12,244
Cancers						
Lip/oral cavity/pharynx	2,705	1,135	29,214	338	0	0
Esophagus	1,455	715	17,356	106	24	493
Stomach	1,440	310	5,102	808	0	0
Rectum	827	250	4,397	522	0	0
Liver/gallbladder/bile ducts	5,663	920	19,031	2,516	181	3,682
Lung	5,388	2,198	34,801	2,724	129	2,988
Cervix uteri	0	0	0	687	72	2,010
Cardiovascular diseases						
Rheumatic HD	45	0	0	76	11	212
Ischemic HD	4,921	1,467	23,279	2,862	124	1,802
Cardiac arrest and other HD	4,141	816	14,119	3,200	0	0
Cerebrovascular disease	5,910	1,225	19,805	4,142	0	0
Respiratory diseases						
Chronic bronchitis	104	47	518	62	0	0
Asthma	261	0	0	242	24	366
Chronic Airway Obstruction	3,254	1,253	12,928	908	0	0
Digestive system diseases						
Peptic ulcer, GI hemorrhage	361	160	2,350	190	51	689
Liver cirrhosis	3,367	1,065	28,538	1,388	0	0
Other diseases						
Diabetes mellitus	4,043	689	11,477	4,139	0	0
Kidney disease	2,071	677	9,831	2,001	0	0
Accidents	3,604	817	20,207	1,479	0	0
SHS-ASSOCIATED DEATH		613	9,768	583		9,799
Lung cancer	5,388	131	2,078	2,724	117	2,584
Ischemic HD	4,921	104	1,652	2,862	86	1,222
Cerebrovascular disease	5,910	353	5,677	4,142	354	5,603
Asthma	261	25	361	242	27	390
TOTAL^b	49,563	14,357	262,722	28,390	1,198	22,043

Note. HD=heart disease; GI=gastrointestinal; SHS=secondhand smoke.

^a Number of deaths among people aged ≥ 35 regardless of their smoking and SHS exposure status.

^b Total deaths from 19 smoking-related diseases which overlap with the four SHS-associated diseases.

1
2
3
4 Table 4 shows the total direct and indirect costs attributed to smoking and SHS exposure by
5
6
7 gender, age, and disease. The total economic costs of smoking and SHS exposure in 2010
8
9
10 amounted to 1,670 million, including US\$828 million (50%) in direct costs, US\$820 million
11
12
13 (49%) in indirect mortality costs, and US\$22 (1%) million in indirect morbidity costs. The share
14
15
16 of the total costs was greater from active smoking (92%) than SHS exposure (8%), and greater
17
18
19 for men (92%) than women (8%). The total economic costs averaged US\$72 per Taiwanese aged
20
21
22 0+ and US\$718 per smoker aged 35+. Based on Taiwan's total cigarette consumption of 1,894
23
24
25 million packs in 2010, the total economic costs averaged US\$0.88 per pack, about 43% the 2010
26
27
28 average retail price of cigarettes (NT\$65 or US\$2.05).[12]
29
30
31

32 Of the US\$828 million in direct healthcare costs, US\$104 million was spent for treating
33
34
35 ischemic heart disease, US\$94 million for stroke, and US\$53 million for lung cancer. Outpatient
36
37
38 expenditures amounted to US\$520 million (63%) while inpatient expenditures were US\$308
39
40
41 million (37%). Among the US\$22 million in indirect morbidity costs, US\$18.7 million was due
42
43
44 to active smoking and US\$3.4 million was due to SHS exposure. The US\$820 million in
45
46
47 mortality costs averaged US\$52,688 per death among the 15,555 premature deaths caused by
48
49
50 smoking or SHS exposure.
51
52
53
54
55
56
57
58
59
60

Table 4. Total Economic Costs of Smoking and Secondhand Smoke (SHS) Exposure by Component of Costs, Gender, Age, and Disease for Adults Aged 35 and Older: Taiwan, 2010 (Unit: US\$1,000)

	Direct costs			Indirect costs		Total economic costs
	Inpatient	Outpatient	Subtotal	Morbidity cost	Mortality cost	
Smoking	268,941	473,003	741,943	18,669	782,595	1,543,208
SHS exposure	39,179	46,894	86,073	3,407	36,968	126,448
Male	274,288	467,438	741,726	18,932	782,515	1,543,173
Female	33,832	52,458	86,290	3,144	37,049	126,484
35-49	61,319	114,908	176,228	10,797	472,607	659,631
50-64	106,579	204,427	311,006	9,601	269,320	589,927
65+	140,222	200,561	340,783	1,678	77,637	420,098
Lung cancer	21,191	31,552	52,743	1,249	86,729	140,721
Ischemic HD	66,157	38,128	104,285	1,615	62,728	168,628
Cerebrovascular	46,055	48,275	94,330	2,943	71,882	169,155
Other diseases ^a	174,717	401,942	576,659	16,270	598,225	1,191,152
Total	308,120	519,896	828,016	22,076	819,564	1,669,656

Note. HD=heart disease. Exchange rate of the NT\$ against US\$1 = 31.642 in 2010.

^a “Other” includes all the rest of smoking or SHS related diseases.

Sensitivity analysis

Table 5 shows that if the prevalence rates of smoking and SHS exposure in 2010 had remained at the same levels as in 2008, the toll of active and passive smoking-attributable losses would have been greater by additional 1,540 deaths and US\$107 million in total economic cost. If the prevalence rates of smoking and SHS exposure were at the mean values of the 2009 and 2010 levels, there would have additional 883 deaths and US\$59 million loss in total economic cost.

If we assumed the annual growth rate of productivity was 6% instead of 4%, total economic costs would be US\$177 million higher. If we used the RR values for those smoking-related diseases reported by the widely cited American study,[24, 25] our estimates of active and passive smoking- attributable premature deaths and total economic costs would increase by 6,958 deaths and US\$505 million.

Table 5. Sensitivity Analysis of Smoking and Secondhand Smoke (SHS) Attributable Mortality (SAM), Direct Healthcare Costs, and Total Economic Costs: Taiwan, 2010

	SAM		Direct costs		Total economic costs	
	No.	% of all deaths*	Amount (US\$ million)	% of NHE	Amount (US\$ million)	% of GDP
MAIN ANALYSIS	15,555	10.75	828	3.38	1,670	0.39
SENSITIVE ANALYSIS						
1. Smoking & SHS exposure prevalence						
Assume the levels in 2008	17,095	11.81	894	3.65	1,777	0.41
Assume the mean levels in 2008 & 2010	16,438	11.36	865	3.53	1,729	0.40
2. Growth rate in productivity						
Assume 6% instead of 4%	15,555	10.75	828	3.38	1,847	0.43
3. Relative risk						
Assume RRs for former smokers = 1	11,140	7.88	629	2.57	1,323	0.31
Assume published RRs in the U.S. ^a	22,513	15.56	1,042	4.25	2,175	0.51

Note. NHE=National personal healthcare expenditure (US\$24.5 billion in 2010); GDP=Gross Domestic Product (US\$430.1 billion in 2010). Exchange rate of the NT\$ against US\$ = 31.642 in 2010.

* In 2010, the number of all-cause deaths among people aged ≥ 0 was 144,709.

^a See Table 12.1 in the 2014 U.S. Surgeon General Report.[25]

DISCUSSION

The direct costs of smoking and SHS exposure in Taiwan amounted to US\$828 million and accounted for 3.4% of Taiwan's personal healthcare expenditures in 2010. Smoking and SHS exposure also led to 15,555 premature deaths, 284,755 years of potential life lost, US\$820 million in indirect costs of productivity losses due to premature deaths, and US\$22 million in indirect costs of time lost from work due to tobacco-related illness. These costs totaled US\$1,670 million, representing 0.4% of Taiwan's gross domestic product (GDP) and averaging about US\$720 per adult smoker.

The proportion of the total costs of smoking and SHS exposure to GDP in Taiwan is smaller than those estimated for other East Asia countries, such as 0.7% for China,[23] and 0.6%-0.8% for South Korea.[26] One possible explanation is because of relatively lower smoking rates in Taiwan. Another explanation may be the underestimation of our direct cost estimates which were based on the NHI claims database. The NHI database only includes health expenditures paid by the NHI, but not copayments or out-of-pocket payments that were spent on non-NHI covered health services such as orthodontics, long-term care, and nursing home care. In 2010, the NHI expenditures only comprised 57% of Taiwan's personal health expenditures.[27] Furthermore, due to limited data accessibility, we only included the NHI spending on inpatient care and Western medicine outpatient care. Other NHI covered health services such as Chinese medicine

1
2
3
4 outpatient care accounted for 16% of the NHI expenditures in 2010.[27] If copayments,
5
6
7 out-of-pocket, and other NHI covered health expenditures are counted, our direct cost estimate
8
9
10 could be considerably larger than US\$828 million.
11

12
13 Our estimated total costs of smoking and SHS exposure are very likely to be underestimated
14
15 for several other reasons. First, we only included 19 diseases in the analyses of
16
17 smoking-attributable costs. Smoking also causes many other diseases such as aortic aneurysm,
18
19 atherosclerosis, pneumonia, Influenza, hip fractures, rheumatoid arthritis, periodontitis, nuclear
20
21 cataract, and tuberculosis,[25] Because the RRs of these diseases for Taiwanese smokers were
22
23 not available in public sources, we did not include them in our analyses. Without considering
24
25 these diseases, our estimates almost certainly underestimate the true costs of smoking, Second,
26
27 we did not include children and young adults under age 35 in the analyses of SHS-attributable
28
29 costs. SHS exposure has been causally linked to adverse health effects on infants and children,
30
31 including low birth weight, sudden infant death syndrome, middle ear disease, chronic
32
33 respiratory symptoms, asthma, and attention deficit hyperactivity disorder [25, 28]. Third, we
34
35 measured SHS exposure based on self-reported exposure in the home and workplace during the
36
37 last week, but did not consider exposure that may have occurred in other public places or at an
38
39 earlier time. It has been shown that self-reported SHS exposure greatly underestimates actual
40
41 exposure assessed by the biomarker such as cotinine level.[29] Therefore, our estimated
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 SHS-attributable costs are most likely to be underestimated. Fourth, in estimating indirect
5
6
7 morbidity costs, we did not count the opportunity costs of relatives or informal caregivers who
8
9
10 took care of patients with smoking-related diseases, productivity losses due to smoking-caused
11
12
13 disability other than inpatient days, and transportation expenses incurred during inpatient and
14
15
16 outpatient visits for the treatment of smoking-related diseases.[23]
17
18

19
20 A previous study by Yang and Fann et al. [8] also included the same 19 smoking-related
21
22
23 diseases and used the same data source for relative risks. They estimated that active smoking
24
25
26 caused 233,223 years of potential life lost (YPLLs) and US\$467 million (after converting into
27
28
29 2010 constant dollars) in excess healthcare costs for 2001. Our corresponding estimates for 2010
30
31
32 are 265,198 years and US\$742 million. Even though adult smoking prevalence declined
33
34
35 significantly during 2001–2010,[5] our 2010 estimates are larger than the 2001 estimates. One
36
37
38 explanation is that Yang and Fann et al. assumed the disease-specific RRs for former smokers
39
40
41 equal to 1, which implies former smokers have the same risk of death or illness as never smokers.
42
43
44 This assumption would lead to underestimation of the smoking-attributable deaths and healthcare
45
46
47 costs in 2001. Another explanation is that the total number of deaths from the 19 smoking-related
48
49
50 diseases increased from 77,953 to 75,003 deaths and Taiwan's personal health expenditures rose
51
52
53 by almost 40% in real term between 2001 and 2010.[13, 27]
54
55
56
57
58
59
60

1
2
3
4 This study indicates that Taiwan's National Health Insurance spent US\$828 million — 6%
5
6
7 of their budget — in 2010 to cover the excess healthcare expenditures caused by smoking and
8
9
10 SHS exposure. These costs were borne by all Taiwan residents including never smokers who
11
12
13 paid for insurance premium. Increasing cigarette taxes will help to offset the external costs of
14
15
16 smoking imposed by smokers on others.
17
18

19
20 Tobacco control programs are costly. In 2009, the government of Taiwan spent US\$15.7
21
22 million US dollars (or NT\$520 million based on the 2009 exchange rate of NT\$33.049 against
23
24
25 US\$1) on tobacco control programs.[30] However, the benefits of tobacco control programs are
26
27
28 substantially larger. Several recent studies have shown that the 2009 Act in Taiwan was
29
30
31 associated with a reduction in adolescent smoking [31] and SHS exposure,[7] and an increase in
32
33
34 adult cessation rates.[32] Assuming a half of the reduction in adult smoking prevalence and SHS
35
36
37 exposure during 2008–2010 was driven by the 2009 Act, our sensitivity analysis results show
38
39
40 that there was a saving in avoided smoking and SHS attributable financial losses by US\$59
41
42
43 million a year in 2010 alone.
44
45
46

47 This study makes several contributions. First, our results indicated that the SHS-attributable
48
49
50 medical costs, indirect morbidity costs, and indirect mortality costs among adults aged ≥ 35 were
51
52
53 not negligible — equaling 12%, 18%, and 5% of the levels of the active smoking-attributable
54
55
56 direct medical costs, indirect morbidity costs, and indirect mortality costs, respectively. Thus, not
57
58
59
60

1
2
3
4 including the impact of SHS exposure would underestimate the true burden of smoking. Second,
5
6
7 we developed an interpolation approach to measure the disease-specific RRs for former smokers
8
9
10 in Taiwan to count smoking-attributable costs for former smokers. Smokers often quit smoking
11
12
13 because they have developed smoking-related illness. Although the risks of heart attack and
14
15
16 stroke falls quickly within the first five years after quitting,[33] the risks of other tobacco-related
17
18
19 diseases takes longer time to reverse after quitting. Therefore, assuming the RRs for former
20
21
22 smokers equal to 1 would certainly underestimate the costs of smoking when the prevalence of
23
24
25 former smokers, especially recent quitters, is high.
26
27
28

29 This study is subject to some limitation. We used the relative risk of death as a proxy for the
30
31
32 relative risk of healthcare utilization and expenditures to estimate the direct cost of smoking
33
34
35 because of data limitation. Also, our measure for disease-specific RR for former smokers was
36
37
38 based on the assumption that the ratio between the excess risk for former smokers and the excess
39
40
41 risk for current smokers is the same for any disease-specific death and all-cause death. To test
42
43
44 the validity of this, we applied this approach to the widely cited American RR data which consist
45
46
47 of disease-specific and all-cause RRs for current and former smokers and are available in the
48
49
50 internet-based SAMMEC software.[24] We found that our derived RRs for former smokers
51
52
53 follow a consistent pattern with the actual RRs for former smokers across diseases, Nevertheless,
54
55
56 epidemiological research is needed to more accurately quantify the disease-specific RRs for
57
58
59
60

1
2
3
4 former smokers in Taiwan. Lastly, we obtained the RRs from previous epidemiological studies
5
6
7 which followed up the vital status of two cohorts established prior to 1992 till 2000.[16, 17] Due
8
9
10 to the changes in smoking behavior over time, the cohort of smokers today are likely different
11
12
13 the cohort 20 years ago; therefore, these RR data may not reflect the true RRs of smokers in
14
15
16 2010. Indeed, the 2014 U.S. Surgeon General's Report has shown that today's cigarette
17
18
19 smokers—both men and women—have a much higher risk for lung cancer and chronic
20
21
22 obstructive pulmonary disease than smokers in the past.
23
24
25

26 Despite the limitations that certainly lead to underestimation of our estimated total
27
28
29 economic costs of smoking and SHS exposure, we found that smoking still imposes a huge
30
31
32 financial burden on Taiwanese society even though smoking prevalence and SHS exposure in
33
34
35 Taiwan have declined in recent years. Thus, sustained tobacco control efforts to encourage
36
37
38 people to quit smoking, prevent smoking uptake by children and young adults, and protect all
39
40
41 people from SHS exposure are needed.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Acknowledgments:** The authors are grateful for the comments provided by Drs. Kung-Yee
5
6 Liang, Teh-wei Hu, Kenneth E Warner, and Frank J Chaloupka.
7
8
9

10
11 **Funding:** This study was funded by Health Promotion Administration, Ministry of Health and
12
13 Welfare, Taiwan (grant CCY 10009-102).
14
15

16
17
18 **Contributorship Statement:** HYS laid out the analytical framework, supervised all the steps of
19
20 data analysis, and revised the manuscript critically for important intellectual content. YWW
21
22 drafted the manuscript particularly on the method parts and helped to review and interpret the
23
24 results. LCC helped obtain all the data and conducted the analyses for this study. YWT
25
26 conceptualized the research idea, obtained the funding, drafted the manuscript and helped
27
28 interpret the results. All authors reviewed and approved the final manuscript.
29
30
31

32
33
34 **Competing interests:** None No additional data are available.
35
36
37

38
39 **Data Sharing Statement:**
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **REFERENCES**
5
6

- 7 1. Campaign for Tobacco-Free Kids. *The Global Cigarette Industry*. June 2013.
8
9
10 http://global.tobaccofreekids.org/files/pdfs/en/Global_Cigarette_Industry_pdf.pdf (accessed 1
11
12
13
14 March 2014)
- 15
16 2. Katanoda K, Jiang Y, Park S, et al. Tobacco control challenges in East Asia: proposals for
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2. Katanoda K, Jiang Y, Park S, et al. Tobacco control challenges in East Asia: proposals for
change in the world's largest epidemic region. *Tob Control* Published Online First: 19 April 2013
doi: 101136/tobaccocontrol-2012-050852.
3. World Health Organization. *Report on the Global Tobacco Epidemic, 2008: the MPOWER
Packag*. Geneva: 2008.
4. Wen CP, Cheng TY, Eriksen MP, et al. The impact of the cigarette market opening in Taiwan.
Tob Control 2005;**14 Suppl 1**:i4-9.
5. Ministry of Health and Welfare, Taiwan. *2012 Taiwan Tobacco Control Annual Report*.
Executive Yuan, Health Promotion Administration, Taipei; 2013.
6. World Health Organization. *Framework Convention on Tobacco Control*. Geneva; 2003.
7. Tsai YW, Chang LC, Sung HY, et al. The impact of smoke-free legislation on reducing
exposure to secondhand smoke: differences across gender and socioeconomic groups. *Tob
Control* Published Online First: 10 September 2013 doi: 101136/tobaccocontrol-2013-051004.
8. Yang MC, Fann CY, Wen CP, et al. Smoking attributable medical expenditures, years of

1
2
3
4 potential life lost, and the cost of premature death in Taiwan. *Tob Control* 2005;**14 Suppl**
5
6
7 **1:i62-70.**

8
9
10 9. Chung CW, Wang JD, Yu CF, et al. Lifetime medical expenditure and life expectancy lost
11
12 attributable to smoking through major smoking related diseases in Taiwan. *Tob Control*
13
14 2007;**16(6):394-9.**

15
16
17
18 10. Sung HY, Max W, Gajalakshmi V, et al., editors. *Economics of Tobacco Toolkit: Assessment*
19
20
21
22
23 *of the Economic Costs of Smoking*. Geneva: World Health Organization; 2011.

24
25
26 11. Lilienfeld AM, Lilienfeld DE. *Foundations of Epidemiology*. 3rd ed. New York: Oxford
27
28
29 University Press, USA; 1994.

30
31
32 12. Ministry of Interior, Taiwan. *2012 Statistical Yearbook of Interior*. Executive Yuan,
33
34
35 Department of Statistics; 2013. <http://sowf.moi.gov.tw/stat/year/list.htm> (accessed 15 August
36
37
38 2013)

39
40
41 13. Ministry of Health and Welfare, Taiwan. *2010 Statistics of Causes of Death*. Executive Yuan.
42
43
44 http://www.mohw.gov.tw/EN/Ministry/Statistic.aspx?f_list_no=474&fod_list_no=3480
45
46
47 (accessed 13 June 2013)

48
49
50 14. Ministry of the Interior, Taiwan. *2010 Abridged life table in Taiwan*. Executive Yuan.
51
52
53
54 <http://sowf.moi.gov.tw/stat/english/elif/elist.htm> (accessed 14 April 2013)

55
56
57 15. Directorate-General of Budget, Accounting and Statistics, Taiwan. 2010 Report on the
58
59
60

1
2
3
4 Manpower Utilization Survey. Executive Yuan.
5
6

7 <http://www.dgbas.gov.tw/lp.asp?ctNode=4987&CtUnit=1183&BaseDSD=7> (accessed 15 May
8
9

10 2013)
11

12
13 16. Wen CP, Tsai SP, Chen CJ, et al. Smoking attributable mortality for Taiwan and its
14
15 projection to 2020 under different smoking scenarios. *Tob Control* 2005;**14 Suppl 1**:i76-80.
16
17

18
19 17. Wen CP, Tsai SP, Chen CJ, et al. The mortality risks of smokers in Taiwan: Part I:
20
21 cause-specific mortality. *Prev Med* 2004;**39**(3):528-35.
22
23

24
25 18. California Environmental Protection Agency. *Proposed Identification of Environmental*
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Tobacco Smoke as a Toxic Air Contaminant. Sacramento, CA: California Environmental
Protection Agency, Office of Environmental Health Hazard Assessment; 2005.

19. Öberg M, Jaakkola MS, Woodward A, et al. Worldwide burden of disease from exposure to
second-hand smoke: a retrospective analysis of data from 192 countries. *Lancet*
2011;**377**(9760):139-46.

20. Öberg M, Jaakkola M, Woodward A. *Second-Hand Smoke: Assessing the environmental
Burden of Disease at National and Local Levels*. Geneva: World Health Organization; 2010.

21. Max W, Sung HY, Shi Y. Deaths from secondhand smoke exposure in the United States:
economic implications. *Am J Public Health* 2012;**102**(11):2173-80.

22. Max W, Rice DP, Sung HY, et al. Valuing human life: estimating the present value of

lifetime earnings. <http://repositories.cdlib.org/ctcre/esarm/PVLE2000> (accessed 8 May 2013)

23. Yang L, Sung HY, Mao Z, et al. Economic costs attributable to smoking in China: update and an 8-year comparison, 2000-2008. *Tob Control* 2011;**20**(4):266-72.

24. Centers for Disease Control and Prevention. Adult SAMMEC: *Smoking-Attributable Mortality, Morbidity, and Economic Costs*. (Online software). Atlanta, GA: Centers for Disease Control and Prevention. https://apps.nccd.cdc.gov/sammec/show_esaf_data.asp (accessed 8 May 2013)

25. US Department of Health and Human Services. *The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General*. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.

26. Kang HY, Kim HJ, Park TK, et al. Economic burden of smoking in Korea. *Tob Control* 2003;**12**(1):37-44.

27. Ministry of Health and Welfare, Taiwan. *2010 National Health Expenditure*. Executive Yuan; November 2011.

28. Max W, Sung HY, Shi Y. Attention deficit hyperactivity disorder among children exposed to secondhand smoke: A logistic regression analysis of secondary data. *Int J Nurs Stud* 2012;**50**:797-806.

- 1
2
3
4 29. Max W, Sung HY, Shi Y. Who is exposed to secondhand smoke? Self-reported and serum
5
6
7 cotinine measured exposure in the US, 1999-2006. *Int J Environ Res Public Health*
8
9
10 2009;**6**(5):1633-48.
11
12
13 30. Chiou S. *Smoking Cessation Services and Tobacco Control* [in Chinese]. Taipei, Taiwan:
14
15 Health Promotion Administration, Ministry of Health and Welfare, R.O.C. (Taiwan); 2012.
16
17 http://www.tma.tw/se_dis/42.asp (accessed 21 May 2014)
18
19
20
21
22 31. Huang SL, Lin IF, Chen CY, et al. Impact of tobacco control policies on adolescent smoking:
23
24 findings from the global youth tobacco survey in Taiwan. *Addiction* 2013;**108**(10):1829-35.
25
26
27
28 32. Chang FC, Sung HY, Zhu SH, et al. Impact of the 2009 Taiwan tobacco hazards prevention
29
30 act on smoking cessation. *Addiction* 2014;**109**(1):140-6.
31
32
33
34 33. US Department of Health and Human Services. How Tobacco Smoke Causes Disease: The
35
36 Biology and Behavioral Basis for Smoking-Attributable Disease. A Report of the Surgeon
37
38 General. Atlanta, GA: Centers for Disease Control and Prevention, National Center for
39
40 Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.
41
42
43
44
45
46
47 <http://www.surgeongeneral.gov/library/reports/tobaccosmoke/> (accessed 11 November 2013)
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 **The Costs of Smoking and Secondhand Smoke Exposure in Taiwan:** **A**
6
7 **Prevalence-Based Annual Cost Approach**
8
9

10
11 **Hai-Yen Sung PhD¹, Li-Chuan Chang MS², Yu-Wen Wen PhD³, Yi-Wen Tsai PhD²**
12
13

14
15
16
17
18 ¹ Institute for Health & Aging, University of California, San Francisco, USA
19

20
21 ² Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan
22

23
24 ³ Clinical Informatics and Medical Statistics Research Center, Chang Gung University, Tao-Yuan,
25
26
27 Taiwan
28

29
30
31
32
33 **Corresponding Author:** Hai-Yen Sung, PhD, Institute for Health & Aging, School of Nursing,
34
35
36 University of California at San Francisco, 3333 California Street, Suite 340, San Francisco, CA
37
38
39 94118. Telephone: 415-502-4697; Fax: 415-476-3915; Email: Hai-Yen.Sung@ucsf.edu
40
41
42
43
44

45 **Keywords:** cost, smoking, secondhand smoke, smoking-attributable fraction, Taiwan
46
47

48
49 **Word Count:** 3963 words (max: 4000 words)
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: To assess the costs of the health effects of cigarette smoking and secondhand smoke (SHS) exposure to society.

Design: Prevalence-based, disease-specific cost-of-illness study. We used an epidemiological population-attributable risk method to determine the costs that can be attributed to smoking and SHS exposure.

Setting: Taiwan.

Participants: All adult population aged 35 and older.

Primary outcome measures: Direct costs of healthcare expenditures spent for treating tobacco-related diseases, indirect mortality costs measured by the value of lost productivity due to tobacco-related premature deaths, and indirect morbidity costs measured by the value of time lost from work due to tobacco-related illness.

Results: In 2010, direct costs of smoking and SHS exposure amounted to US\$828 million, accounting for 3.4% of Taiwan's total personal healthcare expenditures. Smoking and SHS exposure also contributed to 15,555 premature deaths — corresponding to a loss of 284,765 years of life and US\$820 million in productivity — and US\$22 million in indirect morbidity costs. These direct and indirect costs totaled US\$1,670 million, representing 0.4% of Taiwan's gross domestic product (GDP) and averaging about US\$720 per adult smoker. The share of the total costs was greater from active smoking (92%) than SHS exposure (8%), and greater for men (92%) than women (8%).

1
2
3
4
5 **Conclusions:** Smoking and SHS exposure impose a huge financial loss in Taiwan. Sustained
6
7 tobacco control efforts to encourage people to quit smoking, prevent smoking uptake by children
8
9 and young adults, and protect all people from SHS exposure are needed.
10
11
12
13
14
15
16
17
18

19 **Strengths and limitations of this study**

- 20
21 • Little is known about the economic costs of secondhand smoke (SHS) exposure in East
22
23 Asian countries. This is the first study to assess the health effects of smoking by taking into
24
25 account the economic impact of SHS exposure in Taiwan.
26
27
- 28
29 • This study provides evidence on the economic effect of the recent reduction in smoking
30
31 prevalence and SHS exposure on healthcare costs and productivity losses to the Taiwan society,
32
33 as a result of implementing a comprehensive tobacco control program in 2009.
34
35
- 36
37 • Only adults aged 35 and older were included in the study.
38
39
- 40 • The relative risks of healthcare cost for smokers are assumed to be the same as the relative
41
42 risks of death for smokers because of data limitation.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

East Asia is the world's largest tobacco epidemic region, consuming nearly half of total global cigarette consumption.[1] Although all East Asian countries ratified the WHO Framework Convention on Tobacco Control (FCTC) in 2004 or 2015, a recent assessment study [2] revealed that the majority of countries in East Asia lagged behind in implementing the FCTC recommended tobacco control programs according to WHO's MPOWER (Monitoring, Protect, Offer, Warn, Enforcement and Raise) criteria.[3] As of 2010, 37–53% of adult men in East Asia were current smokers and more than 46% of men were exposed to passive smoking at workplaces.[2] To enhance the incentives to implement the promises of the ratified FCTC to reduce the tobacco epidemic in East Asia, update evidence on the economic costs due to active and passive smoking-caused illness, disability, and premature mortality in this region is imperative.

Taiwan is regarded as a model in East Asia in tobacco control.[2] During 1960s and 1970s, smoking prevalence among Taiwanese aged 35 and above exceeded 75% for men and 8–12% for women.[4] In 1987, Taiwan's cigarette market was forced to open to foreign brands, leading to a 6% jump in adult male smoking and a 13% jump in youth smoking within three years.[4] As a consequence, the government launched a series of tobacco control initiatives such as school-based anti-smoking programs and the 1997 Tobacco Hazards Prevention Act through

1
2
3
4 which indoor workplaces and public places became partially smoke-free. [5] In 2002, the
5
6
7 government levied a tobacco tax amounting to five New Taiwan Dollars (NT\$) per pack and
8
9
10 started the Outpatient Smoking Cessation Services. [5] During the period of 1990-2005, smoking
11
12
13 prevalence among men aged 18 and older had declined from 59.4% to 40.0%. [5] Taiwan's
14
15
16 Legislature ratified the WHO FCTC in 2005. Based on the FCTC recommendations, [6] an
17
18
19 amendment to the Tobacco Hazards Prevention Act went into effect in 2009 (hereafter called the
20
21
22 2009 Act) to strengthen existing tobacco control measures by adding graphic warning labels on
23
24
25
26 cigarette packages, extending smoke-free areas to almost all enclosed workplaces and public
27
28
29 places, completely banning tobacco advertisements, promotion and sponsorship, as well as
30
31
32 increasing tobacco taxes.
33

34
35 As a result of the 2009 Act, smoking prevalence among men aged 18 and older in Taiwan
36
37
38 further decreased from 40.0% to 33.5% and exposure to passive smoking in workplaces
39
40
41 decreased substantially from 33.2% to 18.2% between 2005 and 2011. [5, 7] Given this sizeable
42
43
44 reduction in active and passive smoking, it is policy relevant to assess the current level of the
45
46
47 costs of active and passive smoking-attributable illness, disability, and premature mortality, and
48
49
50 to determine whether or not these costs have decreased.
51
52

53
54 Two previous studies estimated the cost of smoking in Taiwan. Using a prevalence-based
55
56
57 approach, Yang et al. estimated that in 2001 smoking contributed to US\$398 million in excess
58
59
60

1
2
3
4 medical expenditures and US\$1,390 million in productivity loss from premature death among

5
6
7 people aged 35 and older [in Taiwan](#).^[8] Using an incidence-based approach, Chung et al.^[9]

8
9
10 estimated that the present value of lifetime smoking-attributable medical costs among people

11
12
13 aged 35 and older ranged from [US\\$291-\\$336 million](#) depending on discount rate [for the year](#)

14
15
16 [2001 in Taiwan](#). There has been no study to update these cost estimates in Taiwan since 2001.

17
18
19 Furthermore, none of studies on the cost of smoking in Taiwan and few of those in the literature

20
21
22 have included any [health](#) costs attributed to passive smoking, also known as secondhand smoke

23
24
25 (SHS).

26
27
28 The main objective of this study is to assess the costs of the health effects of cigarette

29
30
31 smoking and SHS exposure in Taiwan in 2010. This is the first attempt to quantify the economic

32
33
34 costs of SHS exposure in Taiwan. This study will also provide an evaluation on the hypothesis

35
36
37 that implementation of the 2009 Act was associated with decreases in economic costs of smoking

38
39
40 and SHS exposure. Because of the similarity in tobacco epidemic and culture among East Asian

41
42
43 countries, the findings of this study can be served as a valuable reference for understanding the

44
45
46 economic benefits of tobacco control programs in the region.

47 48 49 50 51 52 53 **METHODS**

54
55
56 We considered three components of costs: direct costs of healthcare expenditures spent for

1
2
3
4 treating tobacco-related diseases, indirect mortality costs measured by the value of lost
5
6
7 productivity due to premature death, and indirect morbidity costs measured by the value of time
8
9
10 lost from work due to tobacco-related illness. Prevalence-based, disease-specific cost-of-illness
11
12
13 approach [10] was used to estimate the healthcare expenditures, workloss days, and deaths due to
14
15
16 smoking-related diseases in 2010. We used an epidemiological population-attributable risk
17
18
19 method [11] to determine the smoking-attributable fraction (SAF), which measures the
20
21
22 proportion of expenditures, workloss days, or deaths that can be attributed to smoking, and
23
24
25 applied it to the total measure. A SHS-attributable fraction (SAF^{SHS}) was estimated in a similar
26
27
28 manner. Our analyses focused on adults aged 35 years and older.
29
30

31 **Data sources**

32
33
34
35 Population-based data from the annual Adult Smoking Behavior Survey (ASBS) were used to
36
37
38 determine the prevalence of smoking and SHS exposure. The ASBS is a telephone interview
39
40
41 survey collecting information on individual's demographic characteristics, cigarette smoking and
42
43
44 quitting behavior, and SHS exposure from a nationally representative sample (around 16,000 per
45
46
47 year) of non-institutionalized population aged 18 and older in Taiwan. Disease-specific inpatient
48
49
50 and outpatient expenditures, and number of hospital inpatient days were obtained from the 2010
51
52
53 National Health Insurance (NHI) claims database. Taiwan's NHI, launched in 1995, is a
54
55
56
57
58
59
60

1
2
3
4 mandatory single-payer social health insurance system administered by the government that
5
6
7 provides universal healthcare coverage to virtually all citizens in Taiwan.
8
9

10 Population data came from the 2010 Population Census,[12] number of deaths for each
11
12 disease from the 2010 Statistics of Causes of Death,[13] and life expectancy by age and gender
13
14 from the 2010 life tables.[14] The age- and gender-specific employment rates and monthly
15
16 earnings were obtained from the 2010 Report on the Manpower Utilization Survey.[15]
17
18
19
20
21
22

23 **Smoking-related and SHS-associated diseases**

24
25
26 We included 19 smoking-related diseases which were identified to have a significant association
27
28 between cigarette smoking and mortality risk by two large epidemiological studies conducted in
29
30 Taiwan.[16, 17] We considered six SHS-associated diseases: lung cancer, ischemic heart disease,
31
32
33 cerebravascular disease, chronic obstructive pulmonary disease, asthma, and breast cancer, and
34
35
36 four SHS-associated causes of death: lung cancer, ischemic heart disease, cerebravascular
37
38
39 disease, and asthma as reported by the California Environmental Protection Agency (EPA) [18]
40
41
42
43 and World Health Organization (WHO).[19, 20] Details of these diseases and their diagnosis
44
45
46 codes are listed in Table 1.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Smoking-related disease, secondhand smoke (SHS)-associated disease and cause of death, and relative risk (RR) by disease and gender, Taiwan

Disease (ICD-9 code)	RR of Smoking-related death				RR of SHS-associated disease		RR of SHS-associated cause of death	
	Male		Female		Male	Female	Male	Female
	CS	FS	CS	FS				
SMOKING-RELATED CAUSE OF DEATH								
All causes (001–998)	1.55	1.33	1.89	1.33				
Cancer								
Lip/oral cavity/pharynx (140–149)	2.60	1.96	–	–				
Esophagus (150)	3.18	2.31	15.57	6.40				
Stomach (151)	1.68	1.41	–	–				
Rectum (154)	2.06	1.64	–	–				
Liver/gallbladder/bile ducts	1.46	1.28	5.03	2.49				
Lung (162) ^a	2.73	2.04	3.36	1.88	1.29	1.29	1.29	1.29
Cervix uteri (180)	–	–	5.78	2.77				
Cardiovascular disease								
Rheumatic HD (390–398)	–	–	9.43	4.13				
Ischemic HD (410–414) ^a	2.06	1.64	3.58	1.96	1.49	1.49	1.23	1.23
Cardiac arrest and other HD	1.60	1.36	–	–				
Cerebrovascular disease (430–438) ^a	1.65	1.39	–	–	1.82	1.82	1.65	1.65
Respiratory disease								
Chronic bronchitis (491)	3.13	2.28	–	–				
Asthma (493) ^a	–	–	7.12	3.27	1.97	1.97	<u>1.97</u>	<u>1.97</u>
Chronic Airway Obstruction (496)	2.65	1.99	–	–				
Digestive system disease								
Peptic ulcer, GI hemorrhage	3.00	2.20	22.28	8.89				
Liver cirrhosis (571)	2.01	1.61	–	–				
Other smoking-related disease								
Diabetes mellitus (250)	1.51	1.31	–	–				
Kidney diseases (580–589)	2.23	1.74	–	–				
Accidents (800–949)	1.66	1.40	–	–				
OTHER SHS-ASSOCIATED DISEASE								
COPD (490–492, 496)					1.55	1.55		
Breast cancer (174) ^b					–	1.68		

Note. CS=current smoker; FS=former smoker; HD=heart disease; GI=gastrointestinal; COPD=chronic obstructive pulmonary disease.

^aAlso a SHS-associated disease and SHS-associated cause of death. ^bOnly among premenopausal women younger than age 50.

Smoking-attributable fraction (SAF) and SHS-attributable fraction (SAF^{SHS})

We calculated the SAF for each component of costs by disease, gender, and age group (35-49, 50-64, and ≥ 65 years). Based on two fundamental data elements: smoking prevalence and relative risk (RR) of *disease-specific death* for smoking, the SAF for death measures can be calculated using the following epidemiological formula: [10, 11]

$$\text{SAF}_{ijk} = \frac{P_{jk}^C (RR_{ij}^C - 1)}{P_{jk}^N + P_{jk}^C \times RR_{ij}^C + P_{jk}^F \times RR_{ij}^F} + \frac{P_{jk}^F (RR_{ij}^F - 1)}{P_{jk}^N + P_{jk}^C \times RR_{ij}^C + P_{jk}^F \times RR_{ij}^F} \quad (1)$$

where P^N , P^C , and P^F denote the prevalence of never, current, and former smokers, respectively;

RR^C (or RR^F) denotes the RR of disease-specific death for current (or former) smokers in

comparison to never smokers; the subscript i denotes disease, j denotes gender, and k denotes

age group. Note that $(RR^C - 1)$ denotes the excess risk of disease-specific death for current

smokers over never smokers, and similarly, $(RR^F - 1)$ denotes the excess risk of disease-specific

death for former smokers over never smokers. The first term of Equation (1) is the SAF for

current smokers, and the second term is the SAF for former smokers.

Prevalence rates of current smokers, former smokers, and never smokers among adults aged 35 and older were obtained from the ASBS data. The RR of death for smokers is defined as the

1
2
3
4 ratio of the death rate for smokers to that for never smokers. Given the huge body of scientific
5
6
7 evidence that smokers have a greater risk of mortality compared with never smokers, the RR
8
9
10 should be greater than 1 and the excess risk should be greater than zero. The disease-specific
11
12 relative risks for current smokers (RR^C) specific among Taiwanese adults were taken from the
13
14 two aforementioned epidemiological studies in Taiwan. [16, 17]; however, the disease-specific
15
16 relative risks for former smokers (RR^F) were not available in published sources. Instead of
17
18 adopting the assumption that the RR^F equal 1 and forcing the SAF for former smokers to
19
20 becomes zero as other studies have done, [8, 9] we derived a proxy measure for the RR^F based on
21
22 the assumption that the ratio between the excess risk for former smokers and the excess risk for
23
24 current smokers is the same for any disease-specific death and all-cause death. Fortunately, in the
25
26 same data sources which provided the disease-specific RR^C , the all-cause relative risk for current
27
28 smokers (RRA^C) and the all-cause relative risk for former smokers (RRA^F) were also
29
30 provided. [16, 17] Based on these relative risk data and our assumption, we estimated the
31
32 disease-specific relative risks for former smokers via the following calculation: $(RR^C - 1) \times$
33
34 $(RRA^F - 1) / (RRA^C - 1) + 1.$

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51 To estimate the SAF for healthcare costs, we assumed the RRs of disease-specific
52
53 healthcare cost for current and former smokers are the same as those of disease-specific death for
54
55
56
57 current and former smokers because of data limitation.

Similarly, based on two fundamental data elements: prevalence of SHS exposure and relative risk of disease-specific death or illness for SHS exposure, we calculated the SAF^{SHS} among nonsmokers for each component of costs by disease, gender, and age group as:

$$SAF_{ijk}^{SHS} = \frac{P_{jk}^{SHS} (RR_{ij}^{SHS} - 1)}{P_{jk}^{SHS} (RR_{ij}^{SHS} - 1) + 1} \quad (2)$$

where P^{SHS} denotes the prevalence of SHS exposure among nonsmokers, and RR^{SHS} is the relative risk of disease-specific death or illness for exposed nonsmokers compared to unexposed nonsmokers.

Prevalence rates of SHS exposure among nonsmokers aged 35 and older were obtained from the ASBS data. Nonsmokers include never and former smokers. SHS exposed nonsmokers were either those who either answered ‘yes’ to the question: ‘During the past week has anyone smoked in front of you at home?’ or those who were employed and worked in indoor settings and answered ‘yes’ to the question: ‘During the past week has anyone smoked in front of you at your workplace?’ The RR^{SHS} of disease-specific death and the RR^{SHS} of disease-specific illness were obtained from published sources as reported by the California EPA [18] and WHO.[19, 20]

The relative risks for each disease and each cause of death for current smokers, former

smokers, and SHS exposure are shown in Table 1.

Direct costs

Expenditures paid by the NHI for inpatient hospitalizations and outpatient visits were included as direct costs. Expenditures for prescribed medications during the hospitalizations or outpatient visits were included in the respective inpatient or outpatient expenditure categories. Outpatient visits comprised ambulatory care visits at outpatient or emergency departments of hospitals, and those at western medicine clinics. The smoking-attributable inpatient or outpatient expenditure for each subgroup stratified by disease, gender and age was calculated by multiplying the SAF by the total annual inpatient or outpatient expenditures for that subgroup.

The SHS-attributable inpatient or outpatient expenditure for each disease was derived by multiplying the SAF^{SHS} by the total annual inpatient or outpatient expenditures for that disease among nonsmokers. Because the NHI claims database does not contain individual's smoking status, it does not allow for distinguishing health expenditures for smokers from those for nonsmokers. We determined the amount of total inpatient (similarly, outpatient) expenditures for nonsmokers, INP^{NON} , using the following method as used by two recent studies. [19, 21]

$$INP_{ijk}^{NON} = (INP_{ijk} - INP_{ijk} \times SAF_{ijk}^C) \times (1 - P_{jk}^C) \quad (3)$$

1
2
3
4 where INP is total annual inpatient expenditures among all individuals regardless of smoking
5
6
7 status, P^C is the prevalence of current smokers, and SAF^C is the smoking-attributable fraction for
8
9
10 current smokers as expressed by the first term of Equation (1).
11

12 13 **Indirect mortality costs**

14
15
16 For each subgroup stratified by gender and 5-year age group, we estimated the number of
17
18
19 smoking-attributable deaths (SAD) for each disease by multiplying the SAF by the total number
20
21
22 of deaths for that disease. The number of smoking-attributable years of potential life lost (YPLLs)
23
24
25 was estimated by the product of the SAD and life expectancy remaining at the age of death.
26
27

28
29 Smoking-attributable mortality cost was estimated by the product of the SAD and the present
30
31
32 value of lifetime earnings (PVLEs) expected at the age of death. The PVLEs were calculated by
33
34
35 gender and 5-year age groups based on a human capital approach developed by Max and
36
37
38 colleagues.^[22] A discount rate of 3% was used to convert the earnings into its current worth. A
39
40
41 growth rate of 4%, which was approximately the average annual growth rate of gross domestic
42
43
44 product (GDP) in Taiwan during 2005–2009, was used to take into account the potential growth
45
46
47 of future earnings.
48

49
50 We estimated the number of SHS-attributable deaths, YPLLs, and mortality costs following
51
52
53 the same approach as described for active smoking-attributable indirect mortality measures
54
55
56 except that the estimation only focused on nonsmokers. Total number of deaths among
57
58

1
2
3
4 nonsmokers was determined using the similar method as described for Equation (3).
5
6

7 **Indirect morbidity costs**

8
9
10 We defined smoking-attributable indirect morbidity cost as the value of time lost from work due
11
12 to active or passive smoking-caused illness. The lost time from work is commonly measured by
13
14 the number of workloss days;[23] however, because the data on workloss days by disease were
15
16 not available, we used inpatient days as a proxy. The smoking-attributable indirect morbidity cost
17
18 for each subgroup stratified by disease, gender and age was calculated by the product of the SAF,
19
20 total annual inpatient days for that group, the proportion of the population currently employed,
21
22 and daily earnings among employed persons.
23
24
25
26
27
28
29
30
31

32 Likewise, the SHS-attributable indirect morbidity cost was estimated by multiplying the
33
34 SAF^{SHS} by total annual inpatient days among nonsmokers, employment rate, and daily earnings.
35
36

37
38 Total number of inpatient days among nonsmokers was determined using the similar method as
39
40 described for Equations (3).
41
42
43

44 **Sensitivity analysis**

45
46
47 To evaluate whether or not implementation of the 2009 Act in Taiwan was associated with
48
49 decreases in active and passive smoking-attributable costs, we simulated what would be the cost
50
51 estimates in 2010 by assuming two scenarios: smoking prevalence and SHS exposure rates
52
53 remained at the same levels as in 2008, and smoking prevalence and SHS exposure rates were at
54
55
56
57
58
59
60

1
2
3
4 the mean value of the 2008 and 2010 levels. We also performed sensitivity analyses to see how
5
6
7 sensitive our cost estimates are to different assumptions about the RR values and productivity
8
9
10 growth rates.
11
12
13

14 15 16 17 RESULTS

18
19
20 In 2010, the total population of Taiwan was 23.2 million. Among the 12.4 million adults aged 35
21
22 and older, 2.3 million were current smokers. The smoking prevalence and SHS exposure rates by
23
24 gender and age in 2008 and 2010 are shown in Table 2. In 2010, smoking prevalence rates
25
26 among men were about 10 times as high as those among women: 33.9% versus 3.8% for current
27
28 smoking, and 15.7% versus 1.5% for former smoking. The SHS exposure rates among
29
30 nonsmokers were similar between men and women. From 2008 to 2010, the current smoking
31
32 prevalence among men decreased by nearly 10% and SHS exposure among both genders
33
34 decreased by 13%.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Prevalence (%) of smoking and secondhand smoke (SHS) exposure by gender and age among adults aged 35 and older: Taiwan, 2008 and 2010

	2008 ^a			2010 ^a		
	Smoking		SHS exposure ^b	Smoking		SHS exposure ^b
	CS	FS		CS	FS	
Total	21.6	7.8	28.3	19.2	8.8	24.7
Male	37.5	14.0	28.2	33.9	15.7	24.1
35-49	47.6	15.2	30.0	43.9	16.7	24.6
50-64	37.4	18.7	30.0	31.5	23.6	22.4
65+	29.1	26.8	17.0	19.5	30.1	12.9
Female	4.8	1.2	28.3	3.8	1.5	25.2
35-49	5.9	1.1	33.0	4.8	1.7	29.5
50-64	1.6	1.0	25.8	2.0	1.1	21.5
65+	1.9	1.0	13.8	1.3	1.0	13.2

Note. CS=current smoker; FS=former smoker.

^a Source: Adult Smoking Behavior Survey in Taiwan.

^b Percentage of nonsmokers who are exposed to secondhand smoke in the home or at the workplace.

1
2
3
4 Table 3 shows the deaths and years of potential life lost attributed to smoking and SHS
5
6
7 exposure by cause of death and gender. The three leading causes of smoking-attributable deaths
8
9
10 among men were lung cancer, ischemic heart disease, and chronic airway obstruction, and
11
12 among women were cancers of liver/gallbladder/bile ducts, lung cancer, and ischemic heart
13
14 disease. The leading cause of SHS-associated deaths was stroke for both genders. There was a
15
16 substantial gender difference in the number of active smoking-attributable deaths — 13,744 for
17
18 men and 615 for women. SHS exposure almost equally affected both genders by contributing to
19
20 613 deaths among men and 583 deaths among women. Smoking and SHS exposure contributed
21
22 to a total of 15,555 deaths, which comprised about 20% of the total 19-cause deaths (77,953)
23
24 among persons aged 35+ and 11% of the total all-cause deaths (144,709) among persons aged 0+.
25
26
27
28
29
30
31
32
33
34
35 They were responsible for 284,755 years of potential life lost, averaging 18.3 years per death.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Total Deaths, Smoking-Attributable Mortality (SAM), and Smoking-Attributable Years of Potential Life Lost (SAYPLL) by Cause of Death and Gender among Adults Aged 35 and Older: Taiwan, 2010

Cause of death	Male			Female		
	Death ^a	SAM	SAYPLL	Death ^a	SAM	SAYPLL
SMOKING-RELATED DEATH	<u>49,563</u>	13,744	252,954	<u>28,390</u>	615	12,244
Cancers						
Lip/oral cavity/pharynx	<u>2,705</u>	1,135	29,214	<u>338</u>	0	0
Esophagus	<u>1,455</u>	715	17,356	<u>106</u>	24	493
Stomach	<u>1,440</u>	310	5,102	<u>808</u>	0	0
Rectum	<u>827</u>	250	4,397	<u>522</u>	0	0
Liver/gallbladder/bile ducts	<u>5,663</u>	920	19,031	<u>2,516</u>	181	3,682
Lung	<u>5,388</u>	2,198	34,801	<u>2,724</u>	129	2,988
Cervix uteri	<u>0</u>	0	0	<u>687</u>	72	2,010
Cardiovascular diseases						
Rheumatic HD	<u>45</u>	0	0	<u>76</u>	11	212
Ischemic HD	<u>4,921</u>	1,467	23,279	<u>2,862</u>	124	1,802
Cardiac arrest and other HD	<u>4,141</u>	816	14,119	<u>3,200</u>	0	0
Cerebrovascular disease	<u>5,910</u>	1,225	19,805	<u>4,142</u>	0	0
Respiratory diseases						
Chronic bronchitis	<u>104</u>	47	518	<u>62</u>	0	0
Asthma	<u>261</u>	0	0	<u>242</u>	24	366
Chronic Airway Obstruction	<u>3,254</u>	1,253	12,928	<u>908</u>	0	0
Digestive system diseases						
Peptic ulcer, GI hemorrhage	<u>361</u>	160	2,350	<u>190</u>	51	689
Liver cirrhosis	<u>3,367</u>	1,065	28,538	<u>1,388</u>	0	0
Other diseases						
Diabetes mellitus	<u>4,043</u>	689	11,477	<u>4,139</u>	0	0
Kidney disease	<u>2,071</u>	677	9,831	<u>2,001</u>	0	0
Accidents	<u>3,604</u>	817	20,207	<u>1,479</u>	0	0
SHS-ASSOCIATED DEATH		<u>613</u>	<u>9,768</u>	<u>583</u>	<u>9,799</u>	
Lung cancer	<u>5,388</u>	131	2,078	<u>2,724</u>	117	2,584
Ischemic HD	<u>4,921</u>	104	1,652	<u>2,862</u>	86	1,222
Cerebrovascular disease	<u>5,910</u>	353	5,677	<u>4,142</u>	354	5,603
<u>Asthma</u>	<u>261</u>	<u>25</u>	<u>361</u>	<u>242</u>	<u>27</u>	<u>390</u>
TOTAL^b	<u>49,563</u>	<u>14,357</u>	<u>262,722</u>	<u>28,390</u>	<u>1,198</u>	<u>22,043</u>

Note. HD=heart disease; GI=gastrointestinal; SHS=secondhand smoke.

^a Number of deaths among people aged ≥ 35 regardless of their smoking and SHS exposure status.

^b Total deaths from 19 smoking-related diseases which overlap with the four SHS-associated diseases.

1
2
3
4 Table 4 shows the total direct and indirect costs attributed to smoking and SHS exposure by
5
6
7 gender, age, and disease. The total economic costs of smoking and SHS exposure in 2010
8
9
10 amounted to 1,670 million, including US\$828 million (50%) in direct costs, US\$820 million
11
12 (49%) in indirect mortality costs, and US\$22 (1%) million in indirect morbidity costs. The share
13
14 of the total costs was greater from active smoking (92%) than SHS exposure (8%), and greater
15
16 for men (92%) than women (8%). The total economic costs averaged US\$72 per Taiwanese aged
17
18 0+ and US\$718 per smoker aged 35+. Based on Taiwan's total cigarette consumption of 1,894
19
20 million packs in 2010, the total economic costs averaged US\$0.88 per pack, about 43% the 2010
21
22 average retail price of cigarettes (NT\$65 or US\$2.05).[12]
23
24
25
26
27
28
29
30
31

32 Of the US\$828 million in direct healthcare costs, US\$104 million was spent for treating
33
34 ischemic heart disease, US\$94 million for stroke, and US\$53 million for lung cancer. Outpatient
35
36 expenditures amounted to US\$520 million (63%) while inpatient expenditures were US\$308
37
38 million (37%). Among the US\$22 million in indirect morbidity costs, US\$18.7 million was due
39
40 to active smoking and US\$3.4 million was due to SHS exposure. The US\$820 million in
41
42 mortality costs averaged US\$52,688 per death among the 15,555 premature deaths caused by
43
44 smoking or SHS exposure.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4. Total Economic Costs of Smoking and Secondhand Smoke (SHS) Exposure by Component of Costs, Gender, Age, and Disease for Adults Aged 35 and Older: Taiwan, 2010 (Unit: US\$1,000)

	Direct costs			Indirect costs		Total economic costs
	Inpatient	Outpatient	Subtotal	Morbidity cost	Mortality cost	
Smoking	268,941	473,003	741,943	18,669	782,595	1,543,208
SHS exposure	39,179	46,894	86,073	3,407	<u>36,968</u>	<u>126,448</u>
Male	274,288	467,438	741,726	18,932	<u>782,515</u>	<u>1,543,173</u>
Female	33,832	52,458	86,290	3,144	<u>37,049</u>	<u>126,484</u>
35-49	61,319	114,908	176,228	10,797	<u>472,607</u>	<u>659,631</u>
50-64	106,579	204,427	311,006	9,601	<u>269,320</u>	<u>589,927</u>
65+	140,222	200,561	340,783	1,678	<u>77,637</u>	<u>420,098</u>
Lung cancer	21,191	31,552	52,743	1,249	86,729	140,721
Ischemic HD	66,157	38,128	104,285	1,615	62,728	168,628
Cerebrovascular	46,055	48,275	94,330	2,943	71,882	169,155
Other diseases ^a	174,717	401,942	576,659	16,270	<u>598,225</u>	<u>1,191,152</u>
Total	308,120	519,896	828,016	22,076	<u>819,564</u>	<u>1,669,656</u>

Note. HD=heart disease. Exchange rate of the NT\$ against US\$1 = 31.642 in 2010.

^a “Other” includes all the rest of smoking or SHS related diseases.

Sensitivity analysis

Table 5 shows that if the prevalence rates of smoking and SHS exposure in 2010 had remained at the same levels as in 2008, the toll of active and passive smoking-attributable losses would have been greater by additional 1,540 deaths and US\$107 million in total economic cost. If the prevalence rates of smoking and SHS exposure were at the mean values of the 2009 and 2010 levels, there would have additional 883 deaths and US\$59 million loss in total economic cost.

If we assumed the annual growth rate of productivity was 6% instead of 4%, total economic costs would be US\$177 million higher. If we used the RR values for those smoking-related diseases reported by the widely cited American study,[24, 25] our estimates of active and passive smoking- attributable premature deaths and total economic costs would increase by 6,958 deaths and US\$505 million.

Table 5. Sensitivity Analysis of Smoking and Secondhand Smoke (SHS) Attributable Mortality (SAM), Direct Healthcare Costs, and Total Economic Costs: Taiwan, 2010

	SAM		Direct costs		Total economic costs	
	No.	% of all deaths*	Amount (US\$ million)	% of NHE	Amount (US\$ million)	% of GDP
MAIN ANALYSIS	<u>15,555</u>	<u>10.75</u>	828	3.38	<u>1,670</u>	0.39
SENSITIVE ANALYSIS						
1. Smoking & SHS exposure prevalence						
Assume the levels in 2008	<u>17,095</u>	<u>11.81</u>	894	3.65	<u>1,777</u>	0.41
Assume the mean levels in 2008 & 2010	<u>16,438</u>	<u>11.36</u>	865	3.53	<u>1,729</u>	0.40
2. Growth rate in productivity						
Assume 6% instead of 4%	<u>15,555</u>	<u>10.75</u>	828	3.38	<u>1,847</u>	0.43
3. Relative risk						
Assume RRs for former smokers = 1	<u>11,140</u>	<u>7.88</u>	629	2.57	<u>1,323</u>	0.31
Assume published RRs in the U.S. ^a	<u>22,513</u>	<u>15.56</u>	1,042	4.25	<u>2,175</u>	0.51

Note. NHE=National personal healthcare expenditure (US\$24.5 billion in 2010); GDP=Gross Domestic Product (US\$430.1 billion in 2010). Exchange rate of the NT\$ against US\$ = 31.642 in 2010.

* In 2010, the number of all-cause deaths among people aged ≥ 0 was 144,709.

^a See Table 12.1 in the 2014 U.S. Surgeon General Report.[25]

DISCUSSION

The direct costs of smoking and SHS exposure in Taiwan amounted to US\$828 million and accounted for 3.4% of Taiwan's personal healthcare expenditures in 2010. Smoking and SHS exposure also led to 15,555 premature deaths, 284,755 years of potential life lost, US\$820 million in indirect costs of productivity losses due to premature deaths, and US\$22 million in indirect costs of time lost from work due to tobacco-related illness. These costs totaled US\$1,670 million, representing 0.4% of Taiwan's gross domestic product (GDP) and averaging about US\$720 per adult smoker.

The proportion of the total costs of smoking and SHS exposure to GDP in Taiwan is smaller than those estimated for other East Asia countries, such as 0.7% for China,^[23] and 0.6%-0.8% for South Korea.^[26] One possible explanation is because of relatively lower smoking rates in Taiwan. Another explanation may be the underestimation of our direct cost estimates which were based on the NHI claims database. The NHI database only includes health expenditures paid by the NHI, but not copayments or out-of-pocket payments that were spent on non-NHI covered health services such as orthodontics, long-term care, and nursing home care. In 2010, the NHI expenditures only comprised 57% of Taiwan's personal health expenditures.^[27] Furthermore, due to limited data accessibility, we only included the NHI spending on inpatient care and Western medicine outpatient care. Other NHI covered health services such as Chinese medicine

1
2
3
4 outpatient care accounted for 16% of the NHI expenditures in 2010.[27] If copayments,
5
6
7 out-of-pocket, and other NHI covered health expenditures are counted, our direct cost estimate
8
9
10 could be considerably larger than US\$828 million.
11

12
13 Our estimated total costs of smoking and SHS exposure are very likely to be underestimated
14 for several other reasons. First, we only included 19 diseases in the analyses of
15 smoking-attributable costs. Smoking also causes many other diseases such as aortic aneurysm,
16 atherosclerosis, pneumonia, Influenza, hip fractures, rheumatoid arthritis, periodontitis, nuclear
17 cataract, and tuberculosis,[25] Because the RRs of these diseases for Taiwanese smokers were
18 not available in public sources, we did not include them in our analyses. Without considering
19 these diseases, our estimates almost certainly underestimate the true costs of smoking. Second,
20 we did not include children and young adults under age 35 in the analyses of SHS-attributable
21 costs. SHS exposure has been causally linked to adverse health effects on infants and children,
22 including low birth weight, sudden infant death syndrome, middle ear disease, chronic
23 respiratory symptoms, asthma, and attention deficit hyperactivity disorder [25, 28]. Third, we
24 measured SHS exposure based on self-reported exposure in the home and workplace during the
25 last week, but did not consider exposure that may have occurred in other public places or at an
26 earlier time. It has been shown that self-reported SHS exposure greatly underestimates actual
27 exposure assessed by the biomarker such as cotinine level.[29] Therefore, our estimated
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 SHS-attributable costs are most likely to be underestimated. Fourth, in estimating indirect
5
6 morbidity costs, we did not count the opportunity costs of relatives or informal caregivers who
7
8 took care of patients with smoking-related diseases, productivity losses due to smoking-caused
9
10 disability other than inpatient days, and transportation expenses incurred during inpatient and
11
12 outpatient visits for the treatment of smoking-related diseases.[23]
13
14
15
16
17
18

19
20 A previous study by Yang and Fann et al. [8] also included the same 19 smoking-related
21
22 diseases and used the same data source for relative risks. They estimated that active smoking
23
24 caused 233,223 years of potential life lost (YPLLs) and US\$467 million (after converting into
25
26 2010 constant dollars) in excess healthcare costs for 2001. Our corresponding estimates for 2010
27
28 are 265,198 years and US\$742 million. Even though adult smoking prevalence declined
29
30 significantly during 2001–2010,[5] our 2010 estimates are larger than the 2001 estimates. One
31
32 explanation is that Yang and Fann et al. assumed the disease-specific RRs for former smokers
33
34 equal to 1, which implies former smokers have the same risk of death or illness as never smokers.
35
36 This assumption would lead to underestimation of the smoking-attributable deaths and healthcare
37
38 costs in 2001. Another explanation is that the total number of deaths from the 19 smoking-related
39
40 diseases increased from 77,953 to 75,003 deaths and Taiwan's personal health expenditures rose
41
42 by almost 40% in real term between 2001 and 2010.[13, 27]
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 This study indicates that Taiwan's National Health Insurance spent US\$828 million — 6%
5
6
7 of their budget — in 2010 to cover the excess healthcare expenditures caused by smoking and
8
9
10 SHS exposure. These costs were borne by all Taiwan residents including never smokers who
11
12
13 paid for insurance premium. Increasing cigarette taxes will help to offset the external costs of
14
15
16 smoking imposed by smokers on others.
17

18
19 Tobacco control programs are costly. In 2009, the government of Taiwan spent US\$15.7
20
21
22 million US dollars (or NT\$520 million based on the 2009 exchange rate of NT\$33.049 against
23
24
25 US\$1) on tobacco control programs.^[30] However, the benefits of tobacco control programs are
26
27
28 substantially larger. Several recent studies have shown that the 2009 Act in Taiwan was
29
30
31 associated with a reduction in adolescent smoking ^[31] and SHS exposure,^[7] and an increase in
32
33
34 adult cessation rates.^[32] Assuming a half of the reduction in adult smoking prevalence and SHS
35
36
37 exposure during 2008–2010 was driven by the 2009 Act, our sensitivity analysis results show
38
39
40 that there was a saving in avoided smoking and SHS attributable financial losses by US\$59
41
42
43 million a year in 2010 alone.
44
45

46
47 This study makes several contributions. First, our results indicated that the SHS-attributable
48
49
50 medical costs, indirect morbidity costs, and indirect mortality costs among adults aged ≥ 35 were
51
52
53 not negligible — equaling 12%, 18%, and 5% of the levels of the active smoking-attributable
54
55
56 direct medical costs, indirect morbidity costs, and indirect mortality costs, respectively. Thus, not
57
58
59
60

1
2
3
4 including the impact of SHS exposure would underestimate the true burden of smoking. Second,
5
6
7 we developed an interpolation approach to measure the disease-specific RRs for former smokers
8
9
10 in Taiwan to count smoking-attributable costs for former smokers. Smokers often quit smoking
11
12
13 because they have developed smoking-related illness. Although the risks of heart attack and
14
15
16 stroke falls quickly within the first five years after quitting,[33] the risks of other tobacco-related
17
18
19 diseases takes longer time to reverse after quitting. Therefore, assuming the RRs for former
20
21
22 smokers equal to 1 would certainly underestimate the costs of smoking when the prevalence of
23
24
25 former smokers, especially recent quitters, is high.
26
27

28
29 This study is subject to some limitation. We used the relative risk of death as a proxy for the
30
31
32 relative risk of healthcare utilization and expenditures to estimate the direct cost of smoking
33
34
35 because of data limitation. Also, our measure for disease-specific RR for former smokers was
36
37
38 based on the assumption that the ratio between the excess risk for former smokers and the excess
39
40
41 risk for current smokers is the same for any disease-specific death and all-cause death. To test
42
43
44 the validity of this, we applied this approach to the widely cited American RR data which consist
45
46
47 of disease-specific and all-cause RRs for current and former smokers and are available in the
48
49
50 internet-based SAMMEC software.[24] We found that our derived RRs for former smokers
51
52
53 follow a consistent pattern with the actual RRs for former smokers across diseases, Nevertheless,
54
55
56 epidemiological research is needed to more accurately quantify the disease-specific RRs for
57
58
59
60

1
2
3
4 former smokers in Taiwan. Lastly, we obtained the RRs from previous epidemiological studies
5
6
7 which followed up the vital status of two cohorts established prior to 1992 till 2000.[16, 17] Due
8
9
10 to the changes in smoking behavior over time, the cohort of smokers today are likely different
11
12
13 the cohort 20 years ago; therefore, these RR data may not reflect the true RRs of smokers in
14
15
16 2010. Indeed, the 2014 U.S. Surgeon General’s Report has shown that today’s cigarette
17
18
19 smokers—both men and women—have a much higher risk for lung cancer and chronic
20
21
22 obstructive pulmonary disease than smokers in the past.

23
24
25
26 Despite the limitations that certainly lead to underestimation of our estimated total
27
28
29 economic costs of smoking and SHS exposure, we found that smoking still imposes a huge
30
31
32 financial burden on Taiwanese society even though smoking prevalence and SHS exposure in
33
34
35 Taiwan have declined in recent years. Thus, sustained tobacco control efforts to encourage
36
37
38 people to quit smoking, prevent smoking uptake by children and young adults, and protect all
39
40
41 people from SHS exposure are needed.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Acknowledgments:** The authors are grateful for the comments provided by Drs. Kung-Yee
5
6 Liang, Teh-wei Hu, Kenneth E Warner, and Frank J Chaloupka.
7
8
9

10
11 **Competing interests:** None
12
13

14
15 **Funding:** This study was funded by Health Promotion Administration, Ministry of Health and
16
17 Welfare, Taiwan (grant CCY 10009-102).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Campaign for Tobacco-Free Kids. *The Global Cigarette Industry*. June 2013.
http://global.tobaccofreekids.org/files/pdfs/en/Global_Cigarette_Industry_pdf.pdf (accessed 1 March 2014)
2. Katanoda K, Jiang Y, Park S, et al. Tobacco control challenges in East Asia: proposals for change in the world's largest epidemic region. *Tob Control* Published Online First: 19 April 2013 doi: 101136/tobaccocontrol-2012-050852.
3. World Health Organization. *Report on the Global Tobacco Epidemic, 2008: the MPOWER Packag*. Geneva: 2008.
4. Wen CP, Cheng TY, Eriksen MP, et al. The impact of the cigarette market opening in Taiwan. *Tob Control* 2005;**14 Suppl 1**:i4-9.
5. Ministry of Health and Welfare, Taiwan. *2012 Taiwan Tobacco Control Annual Report*. Executive Yuan, Health Promotion Administration, Taipei; 2013.
6. World Health Organization. *Framework Convention on Tobacco Control*. Geneva; 2003.
7. Tsai YW, Chang LC, Sung HY, et al. The impact of smoke-free legislation on reducing exposure to secondhand smoke: differences across gender and socioeconomic groups. *Tob Control* Published Online First: 10 September 2013 doi: 101136/tobaccocontrol-2013-051004.
8. Yang MC, Fann CY, Wen CP, et al. Smoking attributable medical expenditures, years of

1
2
3
4 potential life lost, and the cost of premature death in Taiwan. *Tob Control* 2005;**14 Suppl**
5
6
7 **1:i62-70.**
8

9
10 9. Chung CW, Wang JD, Yu CF, et al. Lifetime medical expenditure and life expectancy lost
11
12 attributable to smoking through major smoking related diseases in Taiwan. *Tob Control*
13
14 2007;**16(6):394-9.**
15
16
17

18
19
20 10. Sung HY, Max W, Gajalakshmi V, et al., editors. *Economics of Tobacco Toolkit: Assessment*
21
22 *of the Economic Costs of Smoking*. Geneva: World Health Organization; 2011.
23
24

25
26 11. Lilienfeld AM, Lilienfeld DE. *Foundations of Epidemiology*. 3rd ed. New York: Oxford
27
28 University Press, USA; 1994.
29
30

31
32 12. Ministry of Interior, Taiwan. *2012 Statistical Yearbook of Interior*. Executive Yuan,
33
34 Department of Statistics; 2013. <http://sowf.moi.gov.tw/stat/year/list.htm> (accessed 15 August
35
36 2013)
37
38

39
40
41 13. Ministry of Health and Welfare, Taiwan. *2010 Statistics of Causes of Death*. Executive Yuan.
42
43 http://www.mohw.gov.tw/EN/Ministry/Statistic.aspx?f_list_no=474&fod_list_no=3480
44
45 (accessed 13 June 2013)
46
47
48

49
50
51 14. Ministry of the Interior, Taiwan. *2010 Abridged life table in Taiwan*. Executive Yuan.
52
53 <http://sowf.moi.gov.tw/stat/english/elif/elist.htm> (accessed 14 April 2013)
54
55

56
57 15. Directorate-General of Budget, Accounting and Statistics, Taiwan. 2010 Report on the
58
59
60

1
2
3
4 Manpower Utilization Survey. Executive Yuan.
5
6

7 <http://www.dgbas.gov.tw/lp.asp?ctNode=4987&CtUnit=1183&BaseDSD=7> (accessed 15 May
8
9

10 2013)
11

12
13 16. Wen CP, Tsai SP, Chen CJ, et al. Smoking attributable mortality for Taiwan and its
14
15 projection to 2020 under different smoking scenarios. *Tob Control* 2005;**14 Suppl 1**:i76-80.
16
17

18
19 17. Wen CP, Tsai SP, Chen CJ, et al. The mortality risks of smokers in Taiwan: Part I:
20
21 cause-specific mortality. *Prev Med* 2004;**39**(3):528-35.
22
23

24
25 18. California Environmental Protection Agency. *Proposed Identification of Environmental*
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Tobacco Smoke as a Toxic Air Contaminant. Sacramento, CA: California Environmental
Protection Agency, Office of Environmental Health Hazard Assessment; 2005.

19. Öberg M, Jaakkola MS, Woodward A, et al. Worldwide burden of disease from exposure to
second-hand smoke: a retrospective analysis of data from 192 countries. *Lancet*
2011;**377**(9760):139-46.

20. Öberg M, Jaakkola M, Woodward A. *Second-Hand Smoke: Assessing the environmental*
Burden of Disease at National and Local Levels. Geneva: World Health Organization; 2010.

21. Max W, Sung HY, Shi Y. Deaths from secondhand smoke exposure in the United States:
economic implications. *Am J Public Health* 2012;**102**(11):2173-80.

22. Max W, Rice DP, Sung HY, et al. Valuing human life: estimating the present value of

lifetime earnings. <http://repositories.cdlib.org/ctcre/esarm/PVLE2000> (accessed 8 May 2013)

23. Yang L, Sung HY, Mao Z, et al. Economic costs attributable to smoking in China: update and an 8-year comparison, 2000-2008. *Tob Control* 2011;**20**(4):266-72.

24. Centers for Disease Control and Prevention. Adult SAMMEC: *Smoking-Attributable Mortality, Morbidity, and Economic Costs*. (Online software). Atlanta, GA: Centers for Disease Control and Prevention. https://apps.nccd.cdc.gov/sammecc/show_esaf_data.asp (accessed 8 May 2013)

25. US Department of Health and Human Services. *The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General*. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.

26. Kang HY, Kim HJ, Park TK, et al. Economic burden of smoking in Korea. *Tob Control* 2003;**12**(1):37-44.

27. Ministry of Health and Welfare, Taiwan. *2010 National Health Expenditure*. Executive Yuan; November 2011.

28. Max W, Sung HY, Shi Y. Attention deficit hyperactivity disorder among children exposed to secondhand smoke: A logistic regression analysis of secondary data. *Int J Nurs Stud* 2012;**50**:797-806.

1
2
3
4 29. Max W, Sung HY, Shi Y. Who is exposed to secondhand smoke? Self-reported and serum
5 cotinine measured exposure in the US, 1999-2006. *Int J Environ Res Public Health*
6 2009;6(5):1633-48.

7
8
9
10
11
12
13 30. Chiou S. *Smoking Cessation Services and Tobacco Control* [in Chinese]. Taipei, Taiwan:
14 Health Promotion Administration, Ministry of Health and Welfare, R.O.C. (Taiwan); 2012.
15
16 http://www.tma.tw/se_dis/42.asp (accessed 21 May 2014)

17
18
19
20
21
22 31. Huang SL, Lin IF, Chen CY, et al. Impact of tobacco control policies on adolescent smoking:
23 findings from the global youth tobacco survey in Taiwan. *Addiction* 2013;108(10):1829-35.

24
25
26
27
28
29 32. Chang FC, Sung HY, Zhu SH, et al. Impact of the 2009 Taiwan tobacco hazards prevention
30 act on smoking cessation. *Addiction* 2014;109(1):140-6.

31
32
33
34
35 33. US Department of Health and Human Services. How Tobacco Smoke Causes Disease: The
36 Biology and Behavioral Basis for Smoking-Attributable Disease. A Report of the Surgeon
37 General. Atlanta, GA: Centers for Disease Control and Prevention, National Center for
38 Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.
39
40
41 <http://www.surgeongeneral.gov/library/reports/tobaccosmoke/> (accessed 11 November 2013)
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CHEERS Checklist

Items to include when reporting economic evaluations of health interventions

The **ISPOR CHEERS Task Force Report**, *Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluations Publication Guidelines Good Reporting Practices Task Force*, provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: <http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp>

Section/item	Item No	Recommendation	Reported on page No/line No
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, and describe the interventions compared.	page 1, lines 5-7
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	page 2
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions.	pp 4-5. p. 6, para 2
Methods			
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	p4, para 1
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	p4, para 2
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	p5, para 2
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	N/A
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	p6, para 2 & p7 para 1
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	p14, line 38
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	p6. line 57 & p7 para 1
Measurement of effectiveness	11a	<i>Single study-based estimates:</i> Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	N/A



1		11b	<i>Synthesis-based estimates:</i> Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.	N/A
2				
3				
4				
5	Measurement and	12	If applicable, describe the population and methods used to elicit preferences for outcomes.	
6	valuation of preference			
7	based outcomes			pp. 7-8
8				
9	Estimating resources	13a	<i>Single study-based economic evaluation:</i> Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	pp. 10-15
10	and costs			
11		13b	<i>Model-based economic evaluation:</i> Describe approaches and data sources used to estimate resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	N/A
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23	Currency, price date,	14	Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate.	Tables 4-5
24	and conversion			
25				
26				
27				
28				
29	Choice of model	15	Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended.	p7 para 1 & p8
30				
31				
32				
33	Assumptions	16	Describe all structural or other assumptions underpinning the decision-analytical model.	p11 para 1-2
34				
35	Analytical methods	17	Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty.	p11 & p15 para 3 & p. 16, lines 4-10
36				
37				
38				
39				
40				
41				
42				
43	Results			
44	Study parameters	18	Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended.	Tables 1-2
45				
46				
47				
48				
49				
50	Incremental costs and	19	For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios.	N/A
51	outcomes			
52				
53				
54				
55	Characterising	20a	<i>Single study-based economic evaluation:</i> Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact	P22
56	uncertainty			
57				
58				
59				
60				



1		of methodological assumptions (such as discount rate, study	
2		perspective).	& Table 5
3			
4	20b	<i>Model-based economic evaluation</i> : Describe the effects on the	
5		results of uncertainty for all input parameters, and uncertainty	N/A
6		related to the structure of the model and assumptions.	
7	Characterising	21	
8	heterogeneity		
9		If applicable, report differences in costs, outcomes, or cost-	
10		effectiveness that can be explained by variations between	
11		subgroups of patients with different baseline characteristics or	N/A
12		other observed variability in effects that are not reducible by	
13		more information.	
14	Discussion		
15	Study findings,	22	
16	limitations,		
17	generalisability, and		pp. 24–26 &
18	current knowledge		pp. 28–29
19		Summarise key study findings and describe how they support	
20		the conclusions reached. Discuss limitations and the	
21	Other		
22	Source of funding	23	
23			
24		Describe how the study was funded and the role of the funder	p30
25	Conflicts of interest	24	
26			
27		Describe any potential for conflict of interest of study	
28		contributors in accordance with journal policy. In the absence	
29		of a journal policy, we recommend authors comply with	p30
30		International Committee of Medical Journal Editors	
31		recommendations.	

For consistency, the CHEERS Statement checklist format is based on the format of the CONSORT statement checklist

The **ISPOR CHEERS Task Force Report** provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* link or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: <http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp>

The citation for the CHEERS Task Force Report is:

Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. *Value Health* 2013;16:231-50.

